WO2009099467A2 - Cyclosporin compositions - Google Patents

Cyclosporin compositions Download PDF

Info

Publication number
WO2009099467A2
WO2009099467A2 PCT/US2008/076756 US2008076756W WO2009099467A2 WO 2009099467 A2 WO2009099467 A2 WO 2009099467A2 US 2008076756 W US2008076756 W US 2008076756W WO 2009099467 A2 WO2009099467 A2 WO 2009099467A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
cyclosporin
drop
another embodiment
provides
Prior art date
Application number
PCT/US2008/076756
Other languages
French (fr)
Other versions
WO2009099467A3 (en
Inventor
Richard S. Graham
Walter L. Tien
Aileen Morgan
Rhett Schiffman
David A. Hollander
Mayssa Attar
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Priority to EP08872212.9A priority Critical patent/EP2190407B1/en
Priority to MX2010003045A priority patent/MX2010003045A/en
Priority to JP2010525937A priority patent/JP2010540446A/en
Priority to BRPI0816995 priority patent/BRPI0816995A2/en
Priority to AU2008349774A priority patent/AU2008349774A1/en
Priority to CA2700182A priority patent/CA2700182A1/en
Priority to CN200880113223A priority patent/CN101835463A/en
Publication of WO2009099467A2 publication Critical patent/WO2009099467A2/en
Publication of WO2009099467A3 publication Critical patent/WO2009099467A3/en
Priority to IL204614A priority patent/IL204614A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

  • Fig. 1 Mean ( ⁇ SD) cornea cyclosporine A concentrations (semi-log) following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits.
  • Fig. 2 Mean ( ⁇ SD) conjunctiva cyclosporine A concentrations (semi-log) following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits.
  • Fig. 3 Mean ( ⁇ SD) sclera cyclosporine A concentrations (semi-log) following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits.
  • Fig. 4 Mean ( ⁇ SD) eyelid margin cyclosporine A
  • Fig. 5 Mean ( ⁇ SD) nasolacrimal duct cyclosporine A concentrations (semi-log) following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits. DETAILED DESCRIPTION OF THE INVENTION
  • composition comprising cyclosporin A at a concentration of from about 0.0001% (w/v) to less than about 0.05% (w/v) is disclosed herein.
  • compositions of cyclosporin A at a concentration of less than about 0.05% (w/v) can be prepared that will be therapeutically effective.
  • compositions disclosed herein are administered to an eye of a mammal in need thereof to treat loss of corneal sensitivity after surgery affecting the cornea.
  • compositions disclosed herein are administered to an eye of a mammal in need thereof to improve recovery of corneal sensitivity after surgery affecting the cornea.
  • compositions disclosed herein are administered to an eye of a mammal in need thereof to treat post herpetic loss of corneal sensativity. In another embodiment, the compositions disclosed herein are administered to an eye of a mammal in need thereof to treat dry eye disease.
  • Cyclosporin A is a cyclic peptide with immunosuppressive properties having the structure shown above. It is also known by other names including cyclosporine, cyclosporine A, ciclosporin, and ciclosporin A.
  • One embodiment is a method of treating loss of corneal sensitivity comprising topically administering to a mammal in need thereof a composition comprising cyclosporin A at a concentration of from 0.0001% (w/v) to less than about 0.05% (w/v) .
  • the treatment generally comprises administering 10-
  • compositions disclosed herein topically to the eye or eyes of the mammal or human.
  • Loss of corneal sensitivity may be related to a number of factors. For example, loss of corneal sensitivity is often caused by surgery affecting the cornea or by viral infection. Examples of surgery that can cause loss of corneal sensitivity include keratorefractive surgery or penetrating keratoplasty, such as the following procedures : radial keratotomy, photorefractive keratotomy, laser-assisted in situ keratomileusis (LASIK) , laser assisted sub-epithelial keratomileusis (LASEK) , SB-LASIK, EPI-LASIK, and the like.
  • LASIK laser-assisted in situ keratomileusis
  • LASEK laser assisted sub-epithelial keratomileusis
  • SB-LASIK laser assisted sub-epithelial keratomileusis
  • EPI-LASIK EPI-LASIK
  • viral infections that can cause loss of corneal sensitivity include: HSV-I, HSV- 2, VZV, and the like
  • the composition is administered from 1 to 4 times per day. In another embodiment, the composition is administered twice a day.
  • composition is administered only once a day.
  • treat refers to the use of a compound, composition, therapeutically active agent, or drug in the diagnosis, cure, mitigation, treatment, prevention of disease or other undesirable condition, or to affect the structure or any function of the body of man or other animals.
  • the concentration of cyclosporin A is less than about 0.05%. This is intended to mean that the concentration is lower than the concentration in the commercially available 0.05% cyclosporin A emulsion known as Restasis 0 .
  • the concentration of cyclosporin A is from about 0.005% (w/v) to about 0.04% (w/v) . In another embodiment, the concentration of cyclosporin A is from about 0.02% (w/v) to about 0.04% (w/v) .
  • the concentration of cyclosporine A is about 0.005% (w/v) . In another embodiment, the concentration of cyclosporine A is about 0.015% (w/v) .
  • the concentration of cyclosporine A is about 0.0015% (w/v) .
  • the concentration of cyclosporine A is about 0.02% (w/v) .
  • the concentration of cyclosporine A is about 0.03% (w/v) .
  • the concentration of cyclosporine A is about 0.04% (w/v) .
  • a liquid which is ophthalmically acceptable is formulated such that it can be administered topically to the eye.
  • the comfort should be maximized as much as practicable, although sometimes formulation considerations (e.g. drug stability, bioavailability, etc.) may necessitate less than optimal comfort.
  • the liquid should be formulated such that the liquid is tolerable to the patient for topical ophthalmic use.
  • an ophthalmically acceptable liquid should either be packaged for single use, or contain a preservative to prevent contamination over multiple uses.
  • solutions or medicaments are often prepared using a physiological saline solution as a major vehicle. Ophthalmic solutions are often maintained at a comfortable pH with an appropriate buffer system.
  • the formulations may also contain conventional, pharmaceutically acceptable preservatives, stabilizers and surfactants .
  • buffers include, but are not limited to, acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.
  • the composition contains a preservative.
  • Preservatives that may be used in the pharmaceutical compositions disclosed herein include, but are not limited to, cationic preservatives such as quaternary ammonium compounds including benzalkonium chloride, polyquad, and the like; guanidine-based preservatives including PHMB, chlorhexidine, and the like,- chlorobutanol ; mercury preservatives such as thimerosal, phenylmercuric acetate and phenylmercuric nitrate,- and oxidizing preservatives such as stabilized oxychloro complexes (e.g. Purite ) .
  • cationic preservatives such as quaternary ammonium compounds including benzalkonium chloride, polyquad, and the like
  • guanidine-based preservatives including PHMB, chlorhexidine, and the like,- chlorobutanol
  • mercury preservatives such as thimerosal, phenylmercuric acetate and
  • the composition contains a surfactant .
  • a surfactant may be used for assisting in dissolving an excipient or an active agent, dispersing a solid or liquid in a composition, enhancing wetting, modifying drop size, or a number of other purposes.
  • Useful surfactants include, but are not limited to surfactants of the following classes: alcohols; amine oxides,- block polymers; carboxylated alcohol or alkylphenol ethoxylates,- carboxylic acids/fatty acids,- ethoxylated alcohols; ethoxylated alkylphenols,- ethoxylated aryl phenols; ethoxylated fatty acids,- ethoxylated; fatty esters or oils (animal & veg .
  • fatty esters are useful.
  • glycerol esters are useful.
  • glycol esters are useful.
  • lecithin and lecithin derivatives include lecithin and lecithin derivatives.
  • lignin and lignin derivatives include methyl esters; monoglycerides and derivatives; polyethylene glycols; polymeric surfactants; propoxylated & ethoxylated fatty acids, alcohols, or alkyl phenols,- protein-based surfactants; sarcosine derivatives; sorbitan derivatives; sucrose and glucose esters and derivatives .
  • ethoxylate surfactants are useful.
  • An ethoxylate surfactants is one that comprises the moiety -0(CH 2 CH 2 O) n -OH, wherein n is at least about 1.
  • n is from about 1 to about 10,000.
  • n is from 1 to about 1000. In another embodiment, n is from about 1 to about 500.
  • Some ethoxylates contain one ethoxylate moiety. In other words, there is a single ethoxylate chain on each molecule .
  • Examples of surfactants with one ethoxylate moiety include, but are not limited to:
  • Ethoxylated alcohols wherein the alcohol has a single hydroxyl unit; alkylphenol ethoxylates; ethoxylated fatty acids,- fatty acid methyl ester ethoxylates; polyethylene glycols,- and the like.
  • Ethoxylates may comprise more than one ethoxylate moiety. In other words, there may be ethoxylate moieties attached to several different parts of the molecule. Examples include, but are not limited to: block polymers; ethoxylated oils,- sorbitan derivatives; sucrose and glucose ethoxylates,- and the like.
  • Block Polymers These are polymers with the structure A-
  • a and A' are polyethylene chains of 1 or more ethylene units, and B is a polypropylene chain of one or more propylene units. Generally, but not necessarily, A and A' are approximately the same length.
  • a and A' contain from about 2 to about
  • a and A' contain from about 5 to about 100 ethylene units.
  • a and A' contain about 7 to about
  • a and A' contain about 7, about 8, or about 12 ethylene units.
  • B contains from about 25 to about
  • B contains from about 30 to about
  • B contains about 30, about 34, or about 54 propylene units.
  • the molecular weight is from about
  • the molecular weight is from about
  • the molecular weight is about
  • Poloxalene wherein A has about 12 ethylene oxide units
  • B has about 34 propylene oxide units, A 1 has about 12 ethylene oxide units, and the average molecular weight is about 3000.
  • Poloxamer 182 wherein A has about 8 ethylene oxide units, B has about 30 propylene oxide units, A 1 has about
  • Poloxamer 188 wherein A has about 75 ethylene oxide units, B has about 30 propylene oxide units, A 1 has about
  • Poloxamer 331 wherein A has about 7 ethylene oxide units, B has about 54 propylene oxide units, A 1 has about
  • Ethoxylated Alcohols These include but are not limited to:
  • Ethoxylates of linear alcohols having from about 6 to about 20 carbon atoms.
  • the linear alcohol has from about 10 to about 16 carbon atoms. In another embodiment, n is from about 1 to about 100.
  • n is from about 1 to about 50.
  • n is from about 5 to about 50 ethylene oxide units.
  • n is from about 1 to about 20 ethylene oxide units.
  • n is from about 30 to about 50 ethylene oxide units.
  • alkylphenols that are ethoxylated, i.e. the phenolic OH is replaced with an ethoxylate moiety.
  • alkylphenols that are ethoxylated, i.e. the phenolic OH is replaced with an ethoxylate moiety.
  • alkylphenols that are ethoxylated, i.e. the phenolic OH is replaced with an ethoxylate moiety.
  • Octyl Phenol 1.5 Mole Ethoxylate i.e. n is an average of about 1.5
  • Octyl Phenol 5 Mole Ethoxylate i.e. n is an average of about 1.5
  • Octyl Phenol 5 Mole Ethoxylate i.e. n is an average of about 1.5
  • Octyl Phenol 5 Mole Ethoxylate i.e. n is an average of about 1.5
  • Octyl Phenol 5 Mole Ethoxylate i.e. n is an average of about 1.5
  • Octyl Phenol 5 Mole Ethoxylate i.e. n is an average of about 1.5
  • Octyl Phenol 5 Mole Ethoxylate i.e. n is an average of about 1.5
  • Octyl Phenol 5 Mole Ethoxylate i.e. n is an average of about 1.5
  • Octyl Phenol 5 Mole Ethoxylate i.e. n is
  • the following may also be used:
  • n is from about 2 to about 100. In another embodiment, n is from about 5 to about 50. In another embodiment, n is from about 30 to 50.
  • Ethoxylated Fatty Esters or Oils (Animal & Veg.) . These are the products which result from reacting ethylene oxide with a fatty ester or an oil. When a fatty oil is used, the products is a mixture of ethoxylates of the fatty acids present in the oil, ethoxylates of glycerine, ethoxylates of mono and diglycerides, and the like. Specific examples include, but are not limited to:
  • Ethoxylates of the following oils Anise oil, Castor oil, Clove oil, Cassia oil, Cinnamon oil; Almond oil, Corn oil, Arachis oil, Cottonseed oil, Safflower oil, Maize oil, Linseed oil, Rapeseed oil, Soybean oil, Olive oil, Caraway oil, Rosemary oil, Peanut oil, Peppermint oil, Sunflower oil, Eucalyptus oil and Sesame oil; Coriander oil, Lavender oil, Citronella oil, Juniper oil, Lemon oil, Orange oil, Clary sage oil, Nutmeg oil, Tea tree oil, coconut oil, tallow oil, and lard; In one embodiment, from 1 to about 50 moles of ethylene oxide is used per mole of the oil triglyceride.
  • ethylene oxide is used per mole of the oil triglyceride.
  • Ethylene oxide may also react with a fatty acid ester with a formula RCO 2 R' to form RCO 2 (CH 2 CH 2 O) n R' .
  • RCO 2 (CH 2 CH 2 O) n R' where RCO 2 H is a fatty acid and R' is alkyl having from 1 to 6 carbons are contemplated.
  • One embodiment is a fatty acid methyl ester ethoxylate, wherein R' is methyl.
  • RCO 2 H is Why Acid; a 14 carbon fatty acid such as myristic acid; a 16 carbon fatty acid such as palmitic and palmitoleic acid; an 18 carbon fatty acids such as stearic acid, oleic acid, linoleic acid, ⁇ -linolenic acid, and ⁇ -linolenic acid; a 20 carbon fatty acids such as eicosapentaenoic acid; a 22 carbon fatty acids such as arachidic acid; or a 24 carbon carbon fatty acids such as lignoceric acid and nervonic acid.
  • Polyethylene Glycols are ethoxylates that are unsubstituted, or terminated with oxygen on both ends, i.e. HO(CH 2 CH 2 O) n H, Sorbitan Derivatives:
  • polysorbate 80 has an oleate cap as shown in the structure below.
  • Polysorbate 80 (Sum of w, x, y, and z is 20)
  • Polysorbate 80 is POE (20) sorbitan monooleate .
  • the number in parenthesis is the total number of ethylene oxide units on the molecule, and the ending is the number of acid caps and the capping acid.
  • Sorbitan derivatives wherein the total number of ethylene oxide units is from 3 to 30;
  • Sorbitan derivatives wherein the total number of ethylene oxide units is 4, 5, or 20;
  • Sorbitan derivatives wherein the capping acid is laurate, palmitate, stearate, or oleate;
  • the sorbitan derivative may be a POE sorbitan monolaurate,- a POE sorbitan dilaurate,- a POE sorbitan trilaurate,- a POE sorbitan monopalmitate; a POE sorbitan dipalmitate,- a POE sorbitan tripalmitate,- a POE sorbitan monostearate; a POE sorbitan distearate,- a POE sorbitan tristearate; a POE sorbitan monooleate,- a POE sorbitan dioleate,- or a POE sorbitan trioleate; Specific examples include:
  • sucrose and glucose esters and derivatives are similar to the sorbate derivatives described above. In other words, one, several, or all of the hydroxyl moieties of the sugar are ethoxylated, and one or more of the ethoxylate chains are capped with a carboxylic acid. Other sucrose and glucose esters are simply ethoxylated, but do not have a capping carboxylic acid. Other sucrose and glucose esters may be ethoxylated and capped with an alkyl group formed by reaction with an alcohol . Other sucrose and glucose esters may be esters or ethers of the sugars with hydrophobic chains and have ethoxylates substituted in other positions on the sugar.
  • Various useful vehicles may be used in the ophthalmic preparations disclosed herein. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose, and acrylates (e.g. Pemulen ® ) .
  • Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.
  • an ophthalmically acceptable antioxidant includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene .
  • excipient components which may be included in the ophthalmic preparations are chelating agents.
  • a useful chelating agent is edetate disodium, although other chelating agents may also be used in place or in conjunction with it.
  • Compositions may be aqueous solutions or emulsions, or some other acceptable liquid form.
  • one or more oils will be used to form the emulsion, and in some instances one or more surfactants will be required.
  • Suitable oils include, but are not limited to anise oil, castor oil, clove oil, cassia oil, cinnamon oil, almond oil, corn oil, arachis oil, cottonseed oil, safflower oil, maize oil, linseed oil, rapeseed oil, soybean oil, olive oil, caraway oil, rosemary oil, peanut oil, peppermint oil, sunflower oil, eucalpytus oil, sesame oil, and the like.
  • the composition is an aqueous solution.
  • the composition contains no ethanol .
  • the composition contains no hyauronic acid.
  • the composition contains no vitamin E TPGS.
  • the composition contains no cyclodextrin A.
  • the composition contains no cyclodextrin .
  • Polysorbate 80 1.0 10.0
  • compositions P, A, B and C are prepared according to the following procedure.
  • Target pH is 7.5 +/- 0.1.
  • the finished product should be tested for cyclosporine assay, pH, osmolality, viscosity, Purite, sterility, and antimicrobial effectiveness.
  • the finished product should be store at room temperature and protected from light.
  • D and E were prepared by standard methods known in the art .
  • F was prepared as described above for A-C except that Pemulen TR-2 was substituted for carboxymethylcellulose sodium, and the addition of the citrate and borate buffers were omitted.
  • compositions disclosed and used herein provide a therapeutically effective amount of cyclosporin A to a mammal.
  • concentrations of cyclosporin A in the compositions may be significantly lower than those normally associated with a therapeutically effective concentration.
  • one commercial preparation, marketed as Restasis by Allergan, Inc. is a 0.05% cyclosporin A castor oil emulsion.
  • Other compositions currently in development have concentrations of 0.1% or higher.
  • the composition provides more cyclosporin A to the cornea of a person than Composition AA. In another embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition BB.
  • the composition provides more cyclosporin A to the cornea of a person than Composition CC. In one embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition DD.
  • composition provides more cyclosporin A to the cornea of a person than Composition EE.
  • composition provides more cyclosporin A to the cornea of a person than Composition FF.
  • the composition provides more cyclosporin A to the cornea of a person than Composition GG.
  • composition provides more cyclosporin A to the cornea of a person than Composition HH. In another embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition II.
  • composition JJ provides more cyclosporin A to the cornea of a person than Composition JJ.
  • composition provides more cyclosporin A to the cornea of a person than Composition KK.
  • composition provides more cyclosporin A to the cornea of a person than Composition LL.
  • the composition provides more cyclosporin A to the cornea of a person than Composition MM. In one embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition AA.
  • composition provides more cyclosporin A to the conjunctiva of a person than Composition BB.
  • composition provides more cyclosporin A to the conjunctiva of a person than Composition CC.
  • the composition provides more cyclosporin A to the conjunctiva of a person than Composition DD.
  • composition provides more cyclosporin A to the conjunctiva of a person than Composition EE. In another embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition FF.
  • the composition provides more cyclosporin A to the conjunctiva of a person than Composition GG.
  • composition provides more cyclosporin A to the conjunctiva of a person than Composition HH.
  • composition provides more cyclosporin A to the conjunctiva of a person than Composition II.
  • composition provides more cyclosporin A to the conjunctiva of a person than Composition JJ. In another embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition KK.
  • composition provides more cyclosporin A to the conjunctiva of a person than Composition LL.
  • composition provides more cyclosporin A to the conjunctiva of a person than Composition MM.
  • topical administration of one 35 ⁇ L drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 500 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration.
  • topical administration of one 35 ⁇ L drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 1000 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration.
  • topical administration of one 35 ⁇ L drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 1400 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration.
  • topical administration of one 35 ⁇ L drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 2000 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration.
  • topical administration of one 35 ⁇ L drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 2400 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration.
  • topical administration of one 35 ⁇ L drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 17000 ng of cyclosporin A per gram of cornea of said rabbit over a period of 24 hours after said topical administration.
  • said composition is an aqueous solution containing from 0.005% to about 0.04% cyclosporin A, wherein topical administration of one 35 ⁇ L drop of said composition to each eye of a New Zealand rabbit provides at least about 17000 ng of cyclosporin A per gram of cornea to the corneas of said rabbit as determined by: topically administering said composition to each eye of each of 15 female New Zealand white rabbit test subjects; and determining the amount of cyclosporin A in the corneas of three subjects at times of about 0.5 hours, about 2 hours, about 6 hours, about 12 hours, and about 24 after administration to said subject; wherein the amount of cyclosporin A in the cornea is determined only once for each subject.
  • said composition to each eye of a New Zealand rabbit provides at least about 30000 ng of cyclosporin A per gram of cornea to the corneas of said rabbit.
  • said composition to each eye of a New Zealand rabbit provides at least about 45000 ng of cyclosporin A per gram of cornea to the corneas of said rabbit.
  • composition to each eye of a New Zealand rabbit provides at least about 95000 ng of cyclosporin A per gram of cornea to the corneas of said rabbit.
  • said composition to each eye of a New Zealand rabbit provides at least about 155000 ng of cyclosporin A per gram of cornea to the corneas of said rabbit.
  • topical administration of one 35 ⁇ L drop of said composition to each eye of a female New Zealand white rabbit provides to the conjunctivas of said rabbit at least about 6000 ng of cyclosporin A per gram of conjunctiva of said rabbit over a period of 24 hours after said topical administration.
  • said composition is an aqueous solution containing from 0.005% to about 0.04% cyclosporin A, wherein topical administration of one 35 ⁇ L drop of said composition to each eye of a New Zealand rabbit provides at least about 6000 ng of cyclosporin A per gram of conjunctiva to the conjunctivas of said rabbit as determined by: topically administering said composition to each eye of each of 15 female New Zealand white rabbit test subjects; and determining the amount of cyclosporin A in the conjunctivas of three subjects at times of about 0.5 hours, about 2 hours, about 6 hours, about 12 hours, and about 24 after administration to said subject; wherein the amount of cyclosporin A in the conjunctiva is determined only a single time for each subject.
  • said composition to each eye of a New Zealand rabbit provides at least about 5000 ng of cyclosporin A per gram of conjunctiva to the conjunctiva of said rabbit.
  • said composition to each eye of a New Zealand rabbit provides at least about 7000 ng of cyclosporin A per gram of conjunctiva to the conjunctiva of said rabbit.
  • said composition to each eye of a New Zealand rabbit provides at least about 10000 ng of cyclosporin A per gram of conjunctiva to the conjunctiva of said rabbit.
  • said composition to each eye of a New Zealand rabbit provides at least about 17000 ng of cyclosporin A per gram of conjunctiva to the conjunctiva of said rabbit.
  • the blood level of cyclosporin A is less than 0.1 mg/mL for a person for whom the composition has been administered twice a day topically to both eyes in 35 microliter drops for twelve months.
  • the quantitation ranges were 0.2-40 ng/mL in blood, 0.1-200 ng in cornea and conjunctiva, 0.1-100 ng in eyelid margin and nasolacrimal duct, and 0.1-20 ng in sclera and lacrimal gland.
  • composition F Composition E Compositon D ix
  • AUC 0-t AUC 0-t AUC 0-t x (ng*h tl/2 C N ⁇ max (ng*h tl/2 (ng*hr/ tl/2
  • compositions D, E, and F as described above, were used for these experiments.
  • mice Female New Zealand White rabbits weighing 1.8 to 2.6 kg were purchased from Charles River (St. Constant, Quebec, Canada) . A permanent ear tag was used to identify animals.
  • Drinking water that was purified by a reverse osmosis process was offered ad libitum. Water was periodically analyzed for any contaminants that may interfere with the conduct of this study. The manufacturer conducted analysis of animal feed.
  • Animals were euthanized via injection of at least 1 mL of sodium pentobarbital into a marginal ear vein.
  • a ketamine/xylazine cocktail 87 mg/mL ketamine, 13 mg/mL xylazine
  • Cornea The entire cornea was removed from each eye,- weight recorded, placed into separate screw-cap glass 13x100 silanized test tubes and immediately placed on ice. Samples were stored at or below -15 0 C until bioanalysis.
  • the sclera was removed from each eye,- weight recorded, placed into separate screw-cap glass 13x100 silanized test tubes and immediately placed on ice. Samples were stored at or below -15 0 C until bioanalysis.
  • Tissue containing the nasolacrimal duct associated with each eye was removed; weight recorded, placed into screw-cap glass 13x100 silanized test tubes and immediately placed on ice. Samples were stored at or below -15°C until bioanalysis.
  • Blood and ocular tissue samples were stored at or below -15°C until bioanalysis.
  • Bioanalysis Ocular tissue and blood concentrations were quantified using the following method.
  • Ocular tissue samples were extracted by soaking over night with 2.0 mL methanol at 4 0 C. This was followed by a second soak with 2.0 mL methanol and shaking for approximately one hour at room temperature. An aliquot of 1 mL from a total of 4 mL organic extract was removed (all 4 mL were analyzed for lacrimal gland samples) , and internal standard added (20 ⁇ L of 500 ng/mL of CsG) . The methanolic extract was evaporated to dryness and reconstituted with 200 ⁇ L of 2 mM ammonium acetate/0.4% formic acid in 50:50 acetonitrile : water for LC MS/MS analysis.
  • the bioanalytical procedure for analysis of blood samples involved addition of internal standard, CsG (10 ⁇ L of 500 ng/mL) to 0.5 mL aliquots of K3 EDTA- treated rabbit blood. Following incubation of blood sample for 30 minutes at 37 0 C, the samples were acidified with 0.1 N HCL (2 mL) . Methyl t-butyl ether (4 mL) was added to each sample and mixed for 15 minutes. The organic layer was removed and made basic by addition of 0.1 N NaOH (2 mL) .
  • the organic extract was separated from the aqueous layer, evaporated to dryness and reconstituted with 200 ⁇ L of 2 mM ammonium acetate/0.4% formic acid in 50:50 acetonitrile : water for LC MS/MS analysis. Aliquots (50 ⁇ L) of the reconstituted samples were analyzed by LC- MS/MS using a PE Sciex API 3000 mass spectrometer
  • the precursor-product ion pairs used in MRM analysis were: 1203 (MH) + ⁇ 425.5 for CsA and m/z 1217 (MH) + ⁇ 425.5 for IS (Cyclosporin G) .
  • the total analysis time was 5 min, with retention times of CsA and CsG at approximately 1.82 and 1.86 minutes, respectively.
  • Thermo Electron WatsonTM Philadelphia, PA
  • Microsoft " Excel Microsoft " Excel (Redmond, Washington) were used for pharmacokinetic calculations.
  • the pharmacokinetic parameters listed below were calculated using a known non-compartmental approach (see Tang-Lui, et . al . Pharmaceutical Research, VoI 5, No. 4, 1988, 238-241) .
  • the pharmacokinetic data was described using descriptive statistics such as mean and standard deviation whenever possible.
  • Area under the concentration-time profile (AUC) values were reported as a composite AUC and whenever possible, ⁇ standard error of the mean (SEM) .
  • AUC o t (ng-hr/g) Area under concentration time curve from time zero to the last quantifiable time point using the random method for non- sequential sampling t i /2 (hr) Half-life
  • Table 3 Mean cornea concentrations of cyclosporine A following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits.
  • cyclosporine A was rapidly absorbed into the cornea with a peak corneal concentration (C max ) of 4050 ⁇ 1220 ng/g, occurring 0.500 hours post-dose.
  • C max corneal concentration
  • the area under the concentration-time curve (AUC 0 -t) value through the last quantifiable time point was 163000 ⁇ 7000 ng-hr/g and the AUC 0 - 2 4 value was 59000 ng-hr/g.
  • the terminal half -life (ti /2 ) was 41.3 hours and the mean residence time (MRT) was 50.3 hours.
  • Composition E Following a single bilateral ocular instillation of Composition E, cyclosporine A was absorbed into the cornea with C max value of 1100 ⁇ 190 ng/g, occurring 2.00 hours post-dose.
  • the AUC 0 - t value was 76200 ⁇ 3300 ng-hr/g and the AUCo-24 value was 22100 ng-hr/g.
  • the terminal ti /2 was 41.7 hours and the MRT was 56.5 hours.
  • Composition D Following a single bilateral ocular instillation of Composition E, cyclosporine A was absorbed into the cornea with C max value of 1100 ⁇ 190 ng/g, occurring 2.00 hours post-dose.
  • the AUC 0 - t value was 76200 ⁇ 3300 ng-hr/g and the AUCo-24 value was 22100 ng-hr/g.
  • the terminal ti /2 was 41.7 hours and the MRT was 56.5 hours.
  • cyclosporine A was absorbed into the cornea with a C max value of 536 ⁇ 138 ng/g, occurring 6.00 hours post-dose.
  • the AUC 0 - t value was 29300 ⁇ 2000 ng-hr/g and the AUCo-24 value was 9450 ng-hr/g.
  • the terminal ti /2 was 49.8 hours and the MRT was 61.6 hours.
  • Table 5 Mean conj unctiva concentrations of cyclosporine A following a single bilateral topical ocular instillation of one of three 0 . 05% cyclosporine A formulations to New Zealand White rabbits
  • An AUC interval of 0-48 hours was used for calculations
  • An AUC interval of 0-24 hours was used for calculations
  • Composition F Following a single bilateral ocular instillation of Composition F, cyclosporine A was rapidly absorbed into the conjunctiva with a C max value of 4460 ⁇ 650 ng/g, occurring 0.500 hours post-dose.
  • the AUC 0 -t value was 18100 ⁇ 800 ng-hr/g and the AUC 0 - 2 4 value was 17100 ng-hr/g.
  • the terminal ti /2 was 11.3 hours and the MRT was 7.37 hours.
  • composition E Following a single bilateral ocular instillation of Composition E, cyclosporine A was rapidly absorbed into the conjunctiva with a C max value of 2560 ⁇ 1070 ng/g, occurring 0.500 hours post-dose.
  • the AUC 0 -t value was
  • Composition D cyclosporine A was rapidly absorbed into the conjunctiva with a C max value of 694 + 410 ng/g, occurring 0.500 hours post-dose.
  • the AUC 0 -t value was
  • cyclosporine A was rapidly absorbed into the sclera with a C max value of 545 ⁇ 98 ng/g, occurring 0.500 hours post-dose.
  • the AUC 0 - t value was 6110 ⁇ 260 ng-hr/g and the AUCo-24 value was 3900 ng-hr/g.
  • the terminal ti /2 was 29.7 hours and the MRT was 25.3 hours.
  • Composition E Following a single bilateral ocular instillation of Composition E, cyclosporine A was rapidly absorbed into the sclera with a C max value of 136 ⁇ 43 ng/g, occurring 0.500 hours post-dose.
  • the AUC 0 - t value was 2840 ⁇ 150 ng-hr/g and the AUC 0 - 2 4 value was 1560 ng-hr/g.
  • the terminal ti /2 was 24.8 hours and the MRT was 26.7 hours.
  • Composition D Following a single bilateral ocular instillation of Composition E, cyclosporine A was rapidly absorbed into the sclera with a C max value of 136 ⁇ 43 ng/g, occurring 0.500 hours post-dose.
  • the AUC 0 - t value was 2840 ⁇ 150 ng-hr/g and the AUC 0 - 2 4 value was 1560 ng-hr/g.
  • the terminal ti /2 was 24.8 hours and
  • cyclosporine A was absorbed into the sclera with a C max value of 53.0 ⁇ 10.9 ng/g, occurring 6.00 hours post-dose.
  • the AUC 0 - t value was 1040 ⁇ 50 ng-hr/g and the AUCo-24 value was 792 ng-hr/g.
  • the terminal ti /2 was 18.7 hours and the MRT was 23.8 hours.
  • Table 9 Mean eyelid margin concentrations of cyclosporine A following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits.
  • Composition F Following a single bilateral ocular instillation of Composition F, cyclosporine A was rapidly absorbed into the eyelid margin with a C max value of 3120 ⁇ 1040 ng/g, occurring 0.500 hours post-dose.
  • the AUC 0 -t value was 38300 ⁇ 5300 ng-hr/g and the AUC 0 - 2 4 value was 19900 ng-hr/g.
  • the terminal ti /2 was 42.5 hours and the MRT was 40.5 hours.
  • composition E Following a single bilateral ocular instillation of Composition E, cyclosporine A was rapidly absorbed into the eyelid margin with a C max value of 2020 ⁇ 980 ng/g, occurring 0.500 hours post-dose.
  • the AUC 0 -t value was 42200 ⁇ 10800 ng-hr/g and the AUC 0 - 2 4 value was 17600 ng-hr/g.
  • the terminal ti /2 was 38.1 hours and the MRT was 38.4 hours.
  • cyclosporine A was absorbed into the eyelid margin with a C max value of 2450 ⁇ 970 ng/g, occurring 2.00 hours post-dose.
  • the AUC 0 -t value was 27700 ⁇ 3300 ng-hr/g and the AUC 0 - 2 4 value was 18000 ng-hr/g.
  • the terminal ti /2 was 24.4 hours and the MRT was 21.9 hours.
  • Table 11 Mean nasolacrimal duct concentrations of cyclosporine A following a single bilateral topical ocular instillation of one of three 0 . 05% cyclosporine A formulations to New Zealand White rabbits
  • NC Not calculable a An AUC interval of 0 - 144 hours was used for calculations b An AUC interval of 0 - 48 hours was used for calculations c An AUC interval of 0 - 12 hours was used for calculations d A time interval of 0 - 12 hours was used for calculations Composition F
  • Composition F Following a single bilateral ocular instillation of Composition F, cyclosporine A rapidly drained into and was then absorbed into the nasolacrimal duct tissue with a C max value of 195 ⁇ 201 ng/g, occurring 0.500 hours post-dose.
  • the AUC 0 - t value was 2190 ⁇ 350 ng-hr/g and the AUCo-12 value was 478 ⁇ 86 ng-hr/g.
  • the MRT was 17.6 hours .
  • Composition E Following a single bilateral ocular instillation of Composition E, cyclosporine A rapidly drained into and was then absorbed into the nasolacrimal duct tissue with a C max value of 74.4 + 20.9 ng/g, occurring 0.500 hours post-dose.
  • the AUC 0 -t value was 1190 ⁇ 210 ng-hr/g and the AUCo-12 value was 465 ⁇ 106 ng-hr/g.
  • the MRT was 24.7 hours .
  • composition D Following a single bilateral ocular instillation of Composition D, cyclosporine A rapidly drained into and was then absorbed into the nasolacrimal duct tissue with a C max value of 72.0 ⁇ 91.7 ng/g, occurring 0.500 hours post -dose.
  • the AUC 0 - t value was 279 ⁇ 39 ng-hr/g.
  • Table 13 Mean blood concentrations of Cyclosporine A following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits.
  • cyclosporine A was detected at 0 . 5 and 2 hours post -dose in the blood at concentrations of 2 . 21 + 0 . 33 ng/mL and 0 . 463 ⁇ 0 . 021 ng/mL , respectively . Cyclosporine A levels were below the limit of quantitation at all subsequent time points .
  • composition D Following a single bilateral ocular instillation of Composition E, cyclosporine A was detected at 0.5 hours post-dose in the blood at a concentration of 0.441 + 0.126 ng/mL. Cyclosporine A levels were below the limit of quantitation at all subsequent time points.
  • Composition D Following a single bilateral ocular instillation of Composition E, cyclosporine A was detected at 0.5 hours post-dose in the blood at a concentration of 0.441 + 0.126 ng/mL. Cyclosporine A levels were below the limit of quantitation at all subsequent time points.
  • Composition F Administration of Composition F to rabbits generally delivered the highest levels of cyclosporine A to ocular tissues, on average a 5-fold increase in area under the concentration-time profile (AUC) was observed when compared to Composition D.
  • Administration of Composition E to rabbits resulted on average in a 2-fold increase in AUC when compared to Composition D.
  • the pharmacokinetic profile observed following Composition D administration to New Zealand White rabbits in this study was in good agreement with previously reported data.
  • compositions below were prepared in an analogous manner to compositions D, E, and F.
  • Dosing Route Topical ocular • Dosing Regimen: Bilateral, QD (Aqueous) /BID (Composition D) -5days
  • Dose Volume 35 ⁇ L • Time points Day 1 and Day 5-0.5, 2 , 6 , 12, 24 hr post dose
  • compositions are particularly contemplated for use as standards for comparison for characterization of the compositions disclosed herein.
  • compositions are intended to mean those identical to those disclosed in Kanai et . al . , Transplantation Proceedings, VoI 21, No 1 (February), 1989: 3150-3152, which is incorporated by reference herein:
  • Composition AA a solution consisting of 0.025% cyclosporin A, 40 mg/mL alpha cyclodextrin, and water
  • Composition BB a solution consisting of 0.009% cyclosporin A, 20 mg/mL alpha cyclodextrin, and water
  • Composition CC a solution consisting of 0.003% cyclosporin A, 10 mg/mL alpha cyclodextrin, and water.
  • the following composition is intended to mean those identical to that disclosed in Cheeks et . al . , Current Eye Research, VoI 11, No 7 (1992), 641-649, which is incorporated by reference herein:
  • Composition DD an alpha cyclodextrin solution at 40 mg/mL containing 0.025% cyclosporin A.
  • composition is intended to mean that identical that disclosed in Tamilvanan, Stp Pharma Sci Nov-Dec,- 11(6) :421-426, which is incorporated by reference herein, except that the concentration of cyclosporin A is different.
  • Composition EE an emulsion consisting of cyclosporin A (0.05 w/w%) , castor oil (2.5 w/w%) , stearylamine (0.12 w/w%) , ⁇ -tocopherol (0.01 w/w%) , benzalkonium chloride (0.01 w/w%) and water up to 100 w/w% .
  • the following compositions are intended to mean those identical to Samples C-E disclosed in United States Patent No. 5,051,402 (column 7) . The entire disclosure is incorporated herein by reference.
  • Composition FF 0.25 mL/mL of cyclosporin A, 40 mg/mL of ⁇ -cyclodextrin, and 7.79 mg/mL of sodium chloride;
  • Composition GG 0.10 mL/mL of cyclosporin A, 20 mg/mL of ⁇ -cyclodextrin, and 8.40 mg/mL of sodium chloride;
  • Composition HH 0.05 mL/mL of cyclosporin A, 10 mg/mL of ⁇ -cyclodextrin, and 8.70 mg/mL of sodium chloride.
  • the following composition is intended to mean that identical that disclosed in Abdulrizak, Stp Pharma Sci Nov-Dec,- 11(6) :427-432, which is incorporated by reference herein, except that the concentration of cyclosporin A is different.
  • Composition II an emulsion consisting of cyclosporin A (0.05 w/w%) , castor oil (2.5 w/w%) , Poloxamer 188, (0.425 w/w%) , glycerol (2.25 w/w%) , Lipoid E-80 (0.5 w/w%) , stearylamine (0.12 w/w%) , tocopherol (0.01 w/w%) , benzalkonium chloride (0.01 w/w%) , and water.
  • the following composition is intended to mean that identical to that disclosed in Kuwano Mitsuaki et al . Pharm Res 2002 Aug,- 19 (1) : 108-111.
  • Composition JJ a solution consisting of cyclosporine A (0.0865%), ethanol (0.1%), MYS-40 (2%), HPMC (0.3 w/v%) , sodium dihydrogen phosphate (0.2 w/v%) , and disodium EDTA (0.01% w/v%) , sodium chloride to adjust the tonicity to 287 mOsm, and water.
  • Composition KK is intended to mean that disclosed in US20010041671, incorporated by reference herein, as Formulation 1, on Table 1.
  • Composition LL is that disclosed in US20010041671 as Formulation 3, except that the concentration of cyclosporine is reduced.
  • composition is intended to mean that disclosed in Example 2 of US 5,951,971, incorporated herein by reference.
  • Composition MM cyclosporine A (0.025 g) , polyoxyl 40 stearate (0.5g), hydroxypropyl methylcellulose (0.2g), butylated hydroxytoluene (0.0005 g) , ethanol (0.1 g) , sodium chloride (0.73 g) , sodium dihydrogen phosphate (0.2 g) , sodium edethate (0.1 g) , sodium hydroxide to adjust pH to 6.0, and water to make 100 mL .
  • composition provides more cyclosporin A than Composition AA provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition AA, wherein the drop of said composition and the drop of Composition AA are the same volume .
  • composition provides more cyclosporin A than Composition BB provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition BB, wherein the drop of said composition and the drop of Composition BB are the same volume .
  • composition provides more cyclosporin A than Composition CC provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition CC, wherein the drop of said composition and the drop of Composition CC are the same volume .
  • composition provides more cyclosporin A than Composition DD provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition DD, wherein the drop of said composition and the drop of Composition DD are the same volume .
  • composition provides more cyclosporin A than Composition EE provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition EE, wherein the drop of said composition and the drop of Composition EE are the same volume .
  • composition provides more cyclosporin A than Composition FF provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition FF, wherein the drop of said composition and the drop of composition FF are the same volume .
  • composition provides more cyclosporin A than Composition GG provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition GG, wherein the drop of said composition and the drop of composition GG are the same volume .
  • composition provides more cyclosporin A than Composition HH provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition HH, wherein the drop of said composition and the drop of composition HH are the same volume .
  • composition provides more cyclosporin A than Composition II provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition II, wherein the drop of said composition and the drop of composition II are the same volume .
  • composition JJ provides more cyclosporin A than Composition JJ provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition JJ, wherein the drop of said composition and the drop of composition JJ are the same volume .
  • composition provides more cyclosporin A than Composition KK provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition KK, wherein the drop of said composition and the drop of composition KK are the same volume .
  • composition provides more cyclosporin A than Composition LL provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition LL, wherein the drop of said composition and the drop of composition LL are the same volume .
  • composition provides more cyclosporin A than Composition MM provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition MM, wherein the drop of said composition and the drop of composition MM are the same volume .
  • composition provides more cyclosporin A than Composition AA provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition AA, wherein the drop of said composition and the drop of Composition AA are the same volume .
  • composition provides more cyclosporin A than Composition BB provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition BB, wherein the drop of said composition and the drop of Composition BB are the same volume .
  • composition provides more cyclosporin A than Composition CC provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition CC, wherein the drop of said composition and the drop of Composition CC are the same volume .
  • composition provides more cyclosporin A than Composition DD provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition DD, wherein the drop of said composition and the drop of Composition DD are the same volume .
  • composition provides more cyclosporin A than Composition EE provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition EE, wherein the drop of said composition and the drop of Composition EE are the same volume .
  • composition provides more cyclosporin A than Composition FF provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition FF, wherein the drop of said composition and the drop of composition FF are the same volume .
  • composition provides more cyclosporin A than Composition GG provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition GG, wherein the drop of said composition and the drop of composition GG are the same volume .
  • composition provides more cyclosporin A than Composition HH provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition HH, wherein the drop of said composition and the drop of composition HH are the same volume .
  • composition provides more cyclosporin A than Composition II provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition II, wherein the drop of said composition and the drop of composition II are the same volume .
  • composition JJ provides more cyclosporin A than Composition JJ provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition JJ, wherein the drop of said composition and the drop of composition JJ are the same volume .
  • composition provides more cyclosporin A than Composition KK provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition KK, wherein the drop of said composition and the drop of composition KK are the same volume .
  • composition provides more cyclosporin A than Composition LL provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition LL, wherein the drop of said composition and the drop of composition LL are the same volume .
  • composition provides more cyclosporin A than Composition MM provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition MM, wherein the drop of said composition and the drop of composition MM are the same volume .
  • Comparison of two compositions in a person or animal can be carried out by, among other means, administering the claimed composition to one eye and the second composition to the second eye.
  • composition provides more cyclosporin A than Composition AA provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition AA, wherein the drop of said composition and the drop of Composition AA are the same volume .
  • composition provides more cyclosporin A than Composition BB provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition BB, wherein the drop of said composition and the drop of Composition BB are the same volume .
  • composition provides more cyclosporin A than Composition CC provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition CC, wherein the drop of said composition and the drop of Composition CC are the same volume .
  • composition provides more cyclosporin A than Composition DD provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition DD, wherein the drop of said composition and the drop of Composition DD are the same volume .
  • composition provides more cyclosporin A than Composition EE provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition EE, wherein the drop of said composition and the drop of Composition EE are the same volume .
  • composition provides more cyclosporin A than Composition FF provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition FF, wherein the drop of said composition and the drop of composition FF are the same volume .
  • composition provides more cyclosporin A than Composition GG provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition GG, wherein the drop of said composition and the drop of composition GG are the same volume .
  • composition provides more cyclosporin A than Composition HH provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition HH, wherein the drop of said composition and the drop of composition HH are the same volume .
  • composition provides more cyclosporin A than Composition II provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition II, wherein the drop of said composition and the drop of composition II are the same volume .
  • composition JJ provides more cyclosporin A than Composition JJ provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition JJ, wherein the drop of said composition and the drop of composition JJ are the same volume .
  • composition provides more cyclosporin A than Composition KK provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition KK, wherein the drop of said composition and the drop of composition KK are the same volume .
  • composition provides more cyclosporin A than Composition LL provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition LL, wherein the drop of said composition and the drop of composition LL are the same volume .
  • composition provides more cyclosporin A than Composition MM provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition MM, wherein the drop of said composition and the drop of composition MM are the same volume .
  • composition provides more cyclosporin A than Composition AA provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition AA, wherein the drop of said composition and the drop of Composition AA are the same volume .
  • composition provides more cyclosporin A than Composition BB provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition BB, wherein the drop of said composition and the drop of Composition BB are the same volume .
  • composition provides more cyclosporin A than Composition CC provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition CC, wherein the drop of said composition and the drop of Composition CC are the same volume .
  • composition provides more cyclosporin A than Composition DD provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition DD, wherein the drop of said composition and the drop of Composition DD are the same volume .
  • composition provides more cyclosporin A than Composition EE provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition EE, wherein the drop of said composition and the drop of Composition EE are the same volume .
  • composition provides more cyclosporin A than Composition FF provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition FF, wherein the drop of said composition and the drop of composition FF are the same volume.
  • composition provides more cyclosporin A than Composition GG provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition GG, wherein the drop of said composition and the drop of composition GG are the same volume .
  • composition provides more cyclosporin A than Composition HH provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition HH, wherein the drop of said composition and the drop of composition HH are the same volume .
  • composition provides more cyclosporin A than Composition II provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition II, wherein the drop of said composition and the drop of composition II are the same volume.
  • composition JJ provides more cyclosporin A than Composition JJ provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition JJ, wherein the drop of said composition and the drop of composition JJ are the same volume.
  • composition provides more cyclosporin A than Composition KK provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition KK, wherein the drop of said composition and the drop of composition KK are the same volume .
  • composition provides more cyclosporin A than Composition LL provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition LL, wherein the drop of said composition and the drop of composition LL are the same volume .
  • composition provides more cyclosporin A than Composition MM provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition MM, wherein the drop of said composition and the drop of composition MM are the same volume .
  • topical administration of one 35 ⁇ L drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 500 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration.
  • topical administration of one 35 ⁇ L drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 2000 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration.
  • topical administration of one 35 ⁇ L drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 2400 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration.
  • topical administration of one 35 ⁇ L drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 17000 ng of cyclosporin A per gram of cornea of said rabbit over a period of 24 hours after said topical administration.
  • topical administration of one 35 ⁇ L drop of said composition to each eye of a female New Zealand white rabbit provides to the conjunctivas of said rabbit at least about 3300 ng of cyclosporin A per gram of conjunctiva of said rabbit over a period of 24 hours after said topical administration.
  • said composition is an aqueous solution containing from 0.005% to about 0.04% cyclosporin A, wherein topical administration of one 35 ⁇ L drop of said composition to each eye of a New Zealand rabbit provides at least about 17000 ng of cyclosporin A per gram of cornea to the corneas of said rabbit as determined by: topically administering said composition to each eye of each of 15 female New Zealand white rabbit test subjects, and determining the amount of cyclosporin A in the corneas of three subjects at times of about 0.5 hours, about 2 hours, about 6 hours, about 12 hours, and about 24 after administration to said subject, wherein the amount of cyclosporin A in the cornea is determined only once for each subject.
  • said composition is an aqueous solution containing from 0.005% to about 0.04% cyclosporin A, wherein topical administration of one 35 ⁇ L drop of said composition to each eye of a New Zealand rabbit provides at least about 17000 ng of cyclosporin A per gram of conjunctiva to the conjunctivas of said rabbit as determined by: topically administering said composition to each eye of each of 15 female New Zealand white rabbit test subjects, and determining the amount of cyclosporin A in the conjunctivas of three subjects at times of about 0.5 hours, about 2 hours, about 6 hours, about 12 hours, and about 24 after administration to said subject, wherein the amount of cyclosporin A in the conjunctiva is determined only a single time for each subject.
  • compositions are suitable for use in other mammals other than rabbits, including humans.
  • any composition in the claims or elsewhere which is characterized by in vivo rabbit bioavailability testing is contemplated for use in a person or in another mammal .
  • Defining a composition in terms of bioavailability in rabbits should not be construed to limit a method of treatment using the composition to use on rabbits, but treatment with the composition should be construed to include treatment on humans and other mammals.
  • the foregoing description details specific methods and compositions that can be employed to practice the present invention, and represents the best mode contemplated. However, it is apparent for one of ordinary skill in the art that further compositions with the desired pharmacological properties can be prepared in an analogous manner. Thus, however detailed the foregoing may appear in text, it should not be construed as limiting the overall scope hereof; rather, the ambit of the present invention is to be governed only by the lawful construction of the claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed herein are therapeutic methods, compositions, and medicaments related to cyclosporine.

Description

CYCLOSPORIN COMPOSITIONS
by Inventors
Richard S. Graham, Walter L. Tien, Aileen Morgan, Rhett M. Schiffman, David A. Hollander and Mayssa Attar
RELATED APPLICATION
This application claims the benefit of and priority to U.S. Patent Application Serial No. 11/858,200, filed September 20, 2007, a continuation-in-part , which claims priority to U.S. Patent Application Serial No. 11/781,095, filed July 20, 2007, which claims priority to U.S. Provisional Application Serial No. 60/820,239, filed July 25, 2006; U.S. Provisional Application Serial No. 60/829,796, filed October 17, 2006; U.S. Provisional Application Serial No. 60/829,808, filed October 17, 2006; U.S. Provisional Application Serial No. 60/883,525, filed January 5, 2007; U.S. Provisional Application Serial No. 60/916,352, filed May 7, 2007; and U.S. Provisional Application Serial No. 60/869,459, filed
December 11, 2006; each of which is hereby incorporated by reference in their entirety.
BACKGROUND OF THE INVENTION Abnormalities associated with the function of the lacrimal gland or with tearing often cause discomfort to mammals who suffer from these abnormalities. BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 Mean (±SD) cornea cyclosporine A concentrations (semi-log) following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits.
Fig. 2 Mean (±SD) conjunctiva cyclosporine A concentrations (semi-log) following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits.
Fig. 3 Mean (±SD) sclera cyclosporine A concentrations (semi-log) following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits.
Fig. 4 Mean (±SD) eyelid margin cyclosporine A
(concentrations (semi-log) following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits.
Fig. 5 Mean (±SD) nasolacrimal duct cyclosporine A concentrations (semi-log) following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits. DETAILED DESCRIPTION OF THE INVENTION
A composition comprising cyclosporin A at a concentration of from about 0.0001% (w/v) to less than about 0.05% (w/v) is disclosed herein.
We have surprisingly discovered that compositions of cyclosporin A at a concentration of less than about 0.05% (w/v) can be prepared that will be therapeutically effective.
In one embodiment, the compositions disclosed herein are administered to an eye of a mammal in need thereof to treat loss of corneal sensitivity after surgery affecting the cornea.
In another embodiment, the compositions disclosed herein are administered to an eye of a mammal in need thereof to improve recovery of corneal sensitivity after surgery affecting the cornea.
In another embodiment, the compositions disclosed herein are administered to an eye of a mammal in need thereof to treat post herpetic loss of corneal sensativity. In another embodiment, the compositions disclosed herein are administered to an eye of a mammal in need thereof to treat dry eye disease.
-M — Abu-MeGly-
Figure imgf000005_0001
— MeLeu-D-Ala-Ala-MeLeu-Val-MeLeu
Cyclosporin A
Cyclosporin A is a cyclic peptide with immunosuppressive properties having the structure shown above. It is also known by other names including cyclosporine, cyclosporine A, ciclosporin, and ciclosporin A.
Treatment Methods
One embodiment is a method of treating loss of corneal sensitivity comprising topically administering to a mammal in need thereof a composition comprising cyclosporin A at a concentration of from 0.0001% (w/v) to less than about 0.05% (w/v) .
The treatment generally comprises administering 10-
50 μL drops of the compositions disclosed herein topically to the eye or eyes of the mammal or human.
Determination of the number of drops administered per day to the person or mammal to provide effective relief is within the skill of the ordinary artisan.
Loss of corneal sensitivity may be related to a number of factors. For example, loss of corneal sensitivity is often caused by surgery affecting the cornea or by viral infection. Examples of surgery that can cause loss of corneal sensitivity include keratorefractive surgery or penetrating keratoplasty, such as the following procedures : radial keratotomy, photorefractive keratotomy, laser-assisted in situ keratomileusis (LASIK) , laser assisted sub-epithelial keratomileusis (LASEK) , SB-LASIK, EPI-LASIK, and the like.
Examples of viral infections that can cause loss of corneal sensitivity include: HSV-I, HSV- 2, VZV, and the like
In one embodiment, the composition is administered from 1 to 4 times per day. In another embodiment, the composition is administered twice a day.
In another embodiment, the composition is administered only once a day.
In another embodiment, less than 14% of patients suffer ocular burning when the composition is administered only once a day for a period of three months .
In another embodiment, less than 10% of patients suffer ocular burning when the composition is administered only once a day for a period of three months .
In another embodiment, less than 8% of patients suffer ocular burning when the composition is administered only once a day for a period of three months .
For the purposes of this disclosure, "treat," "treating," or "treatment" refer to the use of a compound, composition, therapeutically active agent, or drug in the diagnosis, cure, mitigation, treatment, prevention of disease or other undesirable condition, or to affect the structure or any function of the body of man or other animals.
Compositions
The concentration of cyclosporin A is less than about 0.05%. This is intended to mean that the concentration is lower than the concentration in the commercially available 0.05% cyclosporin A emulsion known as Restasis0.
In another embodiment, the concentration of cyclosporin A is from about 0.005% (w/v) to about 0.04% (w/v) . In another embodiment, the concentration of cyclosporin A is from about 0.02% (w/v) to about 0.04% (w/v) .
In another embodiment, the concentration of cyclosporine A is about 0.005% (w/v) . In another embodiment, the concentration of cyclosporine A is about 0.015% (w/v) .
In another embodiment, the concentration of cyclosporine A is about 0.0015% (w/v) .
In another embodiment, the concentration of cyclosporine A is about 0.02% (w/v) .
In another embodiment, the concentration of cyclosporine A is about 0.03% (w/v) .
In another embodiment, the concentration of cyclosporine A is about 0.04% (w/v) . A liquid which is ophthalmically acceptable is formulated such that it can be administered topically to the eye. The comfort should be maximized as much as practicable, although sometimes formulation considerations (e.g. drug stability, bioavailability, etc.) may necessitate less than optimal comfort. In the case that comfort cannot be maximized, the liquid should be formulated such that the liquid is tolerable to the patient for topical ophthalmic use. Additionally, an ophthalmically acceptable liquid should either be packaged for single use, or contain a preservative to prevent contamination over multiple uses.
For ophthalmic application, solutions or medicaments are often prepared using a physiological saline solution as a major vehicle. Ophthalmic solutions are often maintained at a comfortable pH with an appropriate buffer system. The formulations may also contain conventional, pharmaceutically acceptable preservatives, stabilizers and surfactants .
Various buffers and means for adjusting pH may be used so long as the resulting preparation is ophthalmically acceptable. Accordingly, buffers include, but are not limited to, acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.
In another embodiment, the composition contains a preservative.
Preservatives that may be used in the pharmaceutical compositions disclosed herein include, but are not limited to, cationic preservatives such as quaternary ammonium compounds including benzalkonium chloride, polyquad, and the like; guanidine-based preservatives including PHMB, chlorhexidine, and the like,- chlorobutanol ; mercury preservatives such as thimerosal, phenylmercuric acetate and phenylmercuric nitrate,- and oxidizing preservatives such as stabilized oxychloro complexes (e.g. Purite ) .
In another embodiment, the composition contains a surfactant .
A surfactant may be used for assisting in dissolving an excipient or an active agent, dispersing a solid or liquid in a composition, enhancing wetting, modifying drop size, or a number of other purposes. Useful surfactants include, but are not limited to surfactants of the following classes: alcohols; amine oxides,- block polymers; carboxylated alcohol or alkylphenol ethoxylates,- carboxylic acids/fatty acids,- ethoxylated alcohols; ethoxylated alkylphenols,- ethoxylated aryl phenols; ethoxylated fatty acids,- ethoxylated; fatty esters or oils (animal & veg . ) ; fatty esters,- fatty acid methyl ester ethoxylates ; glycerol esters,- glycol esters,- lanolin-based derivatives; lecithin and lecithin derivatives; lignin and lignin derivatives; methyl esters; monoglycerides and derivatives; polyethylene glycols; polymeric surfactants; propoxylated & ethoxylated fatty acids, alcohols, or alkyl phenols,- protein-based surfactants; sarcosine derivatives; sorbitan derivatives; sucrose and glucose esters and derivatives . In particular, ethoxylate surfactants are useful.
An ethoxylate surfactants is one that comprises the moiety -0(CH2CH2O)n-OH, wherein n is at least about 1.
In one embodiment n is from about 1 to about 10,000.
In another embodiment, n is from 1 to about 1000. In another embodiment, n is from about 1 to about 500.
Some ethoxylates contain one ethoxylate moiety. In other words, there is a single ethoxylate chain on each molecule . Examples of surfactants with one ethoxylate moiety, include, but are not limited to:
Ethoxylated alcohols wherein the alcohol has a single hydroxyl unit; alkylphenol ethoxylates; ethoxylated fatty acids,- fatty acid methyl ester ethoxylates; polyethylene glycols,- and the like.
Ethoxylates may comprise more than one ethoxylate moiety. In other words, there may be ethoxylate moieties attached to several different parts of the molecule. Examples include, but are not limited to: block polymers; ethoxylated oils,- sorbitan derivatives; sucrose and glucose ethoxylates,- and the like.
Block Polymers: These are polymers with the structure A-
B-A' , wherein A and A' are polyethylene chains of 1 or more ethylene units, and B is a polypropylene chain of one or more propylene units. Generally, but not necessarily, A and A' are approximately the same length.
In one embodiment, A and A' contain from about 2 to about
200 ethylene units.
In another embodiment, A and A' contain from about 5 to about 100 ethylene units.
In another embodiment, A and A' contain about 7 to about
15 ethylene units.
In another embodiment, A and A' contain about 7, about 8, or about 12 ethylene units. In another embodiment, B contains from about 25 to about
100 propylene units.
In another embodiment, B contains from about 30 to about
55 propylene units.
In another embodiment, B contains about 30, about 34, or about 54 propylene units.
In another embodiment, the molecular weight is from about
1000 to about 20000.
In another embodiment, the molecular weight is from about
2000 to about 10000. In another embodiment, the molecular weight is about
2500, about 3000, about 3800, or about 8400.
These include but are not limited to:
Poloxalene: wherein A has about 12 ethylene oxide units,
B has about 34 propylene oxide units, A1 has about 12 ethylene oxide units, and the average molecular weight is about 3000.
Poloxamer 182 : wherein A has about 8 ethylene oxide units, B has about 30 propylene oxide units, A1 has about
8 ethylene oxide units, and the average molecular weight is about 2500
Poloxamer 188: wherein A has about 75 ethylene oxide units, B has about 30 propylene oxide units, A1 has about
75 ethylene oxide units, and the average molecular weight is about 8400. Poloxamer 331: wherein A has about 7 ethylene oxide units, B has about 54 propylene oxide units, A1 has about
7 ethylene oxide units, and the average molecular weight is about 3800;
Ethoxylated Alcohols These include but are not limited to:
Ethoxylates of linear alcohols having from about 6 to about 20 carbon atoms.
In one embodiment, the linear alcohol has from about 10 to about 16 carbon atoms. In another embodiment, n is from about 1 to about 100.
In another embodiment, n is from about 1 to about 50.
In another embodiment, n is from about 5 to about 50 ethylene oxide units.
In another embodiment, n is from about 1 to about 20 ethylene oxide units.
In another embodiment, n is from about 30 to about 50 ethylene oxide units.
Ethoxylated Alkylphenols
These are alkylphenols that are ethoxylated, i.e. the phenolic OH is replaced with an ethoxylate moiety. These include but are not limited to: octylphenol ethoxylate, i.e. C8H17Ph(OCH2CH2O)nH. nonylphenol ethoxylate, i.e. C9H19Ph(OCH2CH2O)nH. alkyphenols of the above formula wherein n is from about 1 to about 100. alkyphenols of the above formula wherein n is from about 1 to about 50. alkyphenols of the above formula wherein n is from about
9 to about 15.
Octyl Phenol 1.5 Mole Ethoxylate (i.e. n is an average of about 1.5) ; Octyl Phenol 5 Mole Ethoxylate;; Octyl Phenol 7 Mole Ethoxylate; Octyl Phenol 9 Mole Ethoxylate; Octyl Phenol 12 Mole Ethoxylate; Octyl Phenol 40 Mole Ethoxylate; Nonyl Phenol 1.5 Mole Ethoxylate; Nonyl Phenol 4 Mole Ethoxylate; Nonyl Phenol 6 Mole Ethoxylate; Nonyl Phenol 9 Mole Ethoxylate; Nonyl Phenol
10 Mole Ethoxylate; Nonyl Phenol 10.5 Mole Ethoxylate; Nonyl Phenol 12 Mole Ethoxylate; Nonyl Phenol 15 Mole Ethoxylate; Nonyl Phenol 15 Mole Ethoxylate; Nonyl Phenol 30 Mole Ethoxylate; and Nonyl Phenol 40 Mole Ethoxylate; Ethoxylated Fatty Acids,
These include but are not limited to: ethoxylates which are esterified to form either: monoesters, i.e. RCO2(CH2CH2O)nOH, where RCO2H is a fatty acid; or diesters, i.e. RCO2 (CH2CH2O) nC (=0) R.
Fatty acids include, but are not limited to: Saturated fatty acids, which have no C=C moieties and include myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid. Unsaturated fatty acids, including the following: monounsaturated fatty acids, which have one C=C group such as palmitoleic acid, oleic acid, and nervonic acid; diunsaturated fatty acids, which have two C=C groups, such as linoleic acid; triiunsaturated fatty acids, which have three C=C groups, such as α-linolenic acid and γ-linolenic acid; tetraunsaturated fatty acids, which have four C=C groups, such as arachidonic acid; and pentaunsaturated fatty acids, which have five C=C groups, such as eicosapentaenoic acid. The following may also be used:
Laurie Acid; 14 carbon fatty acids such as myristic acid; 16 carbon fatty acids such as palmitic and palmitoleic acid; 18 carbon fatty acids such as stearic acid, oleic acid, linoleic acid, α-linolenic acid, and γ-linolenic acid; 20 carbon fatty acids such as eicosapentaenoic acid; 22 carbon fatty acids such as arachidic acid; and 24 carbon carbon fatty acids such as lignoceric acid and nervonic acid.
In one embodiment, n is from about 2 to about 100. In another embodiment, n is from about 5 to about 50. In another embodiment, n is from about 30 to 50. Ethoxylated Fatty Esters or Oils (Animal & Veg.) . These are the products which result from reacting ethylene oxide with a fatty ester or an oil. When a fatty oil is used, the products is a mixture of ethoxylates of the fatty acids present in the oil, ethoxylates of glycerine, ethoxylates of mono and diglycerides, and the like. Specific examples include, but are not limited to:
Ethoxylates of the following oils: Anise oil, Castor oil, Clove oil, Cassia oil, Cinnamon oil; Almond oil, Corn oil, Arachis oil, Cottonseed oil, Safflower oil, Maize oil, Linseed oil, Rapeseed oil, Soybean oil, Olive oil, Caraway oil, Rosemary oil, Peanut oil, Peppermint oil, Sunflower oil, Eucalyptus oil and Sesame oil; Coriander oil, Lavender oil, Citronella oil, Juniper oil, Lemon oil, Orange oil, Clary sage oil, Nutmeg oil, Tea tree oil, coconut oil, tallow oil, and lard; In one embodiment, from 1 to about 50 moles of ethylene oxide is used per mole of the oil triglyceride. In another embodiment, from about 30 to about 40 moles of ethylene oxide is used per mole of the oil triglyceride. Ethylene oxide may also react with a fatty acid ester with a formula RCO2R' to form RCO2(CH2CH2O)nR' . Thus, surfactants having the formula RCO2(CH2CH2O)nR', where RCO2H is a fatty acid and R' is alkyl having from 1 to 6 carbons are contemplated.
One embodiment is a fatty acid methyl ester ethoxylate, wherein R' is methyl.
In another embodiment, RCO2H is Laurie Acid; a 14 carbon fatty acid such as myristic acid; a 16 carbon fatty acid such as palmitic and palmitoleic acid; an 18 carbon fatty acids such as stearic acid, oleic acid, linoleic acid, α-linolenic acid, and γ-linolenic acid; a 20 carbon fatty acids such as eicosapentaenoic acid; a 22 carbon fatty acids such as arachidic acid; or a 24 carbon carbon fatty acids such as lignoceric acid and nervonic acid. Polyethylene Glycols are ethoxylates that are unsubstituted, or terminated with oxygen on both ends, i.e. HO(CH2CH2O)nH, Sorbitan Derivatives:
These are ethoxylated sorbates having a fatty acid capping one or more of the ethoxylated chains . For example, polysorbate 80 has an oleate cap as shown in the structure below.
Figure imgf000016_0001
Polysorbate 80 (Sum of w, x, y, and z is 20)
These compounds are named as POE (w+x+y+z) sorbitan mono (or di- or tri-) fatty acid.
For example, Polysorbate 80 is POE (20) sorbitan monooleate .
Thus, the number in parenthesis is the total number of ethylene oxide units on the molecule, and the ending is the number of acid caps and the capping acid.
These include but are not limited to:
Sorbitan derivatives wherein the total number of ethylene oxide units is from 3 to 30;
Sorbitan derivatives wherein the total number of ethylene oxide units is 4, 5, or 20;
Sorbitan derivatives wherein the capping acid is laurate, palmitate, stearate, or oleate;
The sorbitan derivative may be a POE sorbitan monolaurate,- a POE sorbitan dilaurate,- a POE sorbitan trilaurate,- a POE sorbitan monopalmitate; a POE sorbitan dipalmitate,- a POE sorbitan tripalmitate,- a POE sorbitan monostearate; a POE sorbitan distearate,- a POE sorbitan tristearate; a POE sorbitan monooleate,- a POE sorbitan dioleate,- or a POE sorbitan trioleate; Specific examples include:
POE (20) sorbitan monolaurate,- POE (4) sorbitan monolaurate,- POE (20) sorbitan monopalmitate; POE (20) monostearate; POE (20) sorbitan monostearate; POE (4) sorbitan monostearate; POE (20) sorbitan tristearate; POE (20) sorbitan monoleate,- POE (20) sorbitan 15 monoleate; POE (5) sorbitan 10 monoleate; POE (20) sorbitan trioleate; and
Sucrose and Glucose Esters and Derivatives: Although there are a number of sucrose and glucose based surfactants, some sucrose and glucose esters and derivatives are similar to the sorbate derivatives described above. In other words, one, several, or all of the hydroxyl moieties of the sugar are ethoxylated, and one or more of the ethoxylate chains are capped with a carboxylic acid. Other sucrose and glucose esters are simply ethoxylated, but do not have a capping carboxylic acid. Other sucrose and glucose esters may be ethoxylated and capped with an alkyl group formed by reaction with an alcohol . Other sucrose and glucose esters may be esters or ethers of the sugars with hydrophobic chains and have ethoxylates substituted in other positions on the sugar.
Various useful vehicles may be used in the ophthalmic preparations disclosed herein. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose, and acrylates (e.g. Pemulen®) .
Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.
In a similar vein, an ophthalmically acceptable antioxidant includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene .
Other excipient components which may be included in the ophthalmic preparations are chelating agents. A useful chelating agent is edetate disodium, although other chelating agents may also be used in place or in conjunction with it.
Compositions may be aqueous solutions or emulsions, or some other acceptable liquid form. For an emulsion, one or more oils will be used to form the emulsion, and in some instances one or more surfactants will be required. Suitable oils include, but are not limited to anise oil, castor oil, clove oil, cassia oil, cinnamon oil, almond oil, corn oil, arachis oil, cottonseed oil, safflower oil, maize oil, linseed oil, rapeseed oil, soybean oil, olive oil, caraway oil, rosemary oil, peanut oil, peppermint oil, sunflower oil, eucalpytus oil, sesame oil, and the like.
In one embodiment, the composition is an aqueous solution.
In another embodiment, the composition contains no ethanol .
In another embodiment, the composition contains no hyauronic acid.
In another embodiment, the composition contains no vitamin E TPGS.
In another embodiment, the composition contains no cyclodextrin A.
In another embodiment, the composition contains no cyclodextrin .
Example 1
Ingredients Percent Amount needed (g) Ingredients for a 1 liter (% w/v) batch
Cyclosporine 0% for Placebo 0 grams for (P) Placebo (P)
0.03% (A) 0.30 (A) 0.04% (B) 0.40 (B)
0.05% (C) 0.5 (C)
Carboxymethylcellulose 0.5 5.0 sodium
Polysorbate 80 1.0 10.0
Glycerin 1.0 10.0
Mannitol 0.5 5.0
Sodium Citrate 0.4 4.0 Dihydrate
Boric Acid 0.25 2.5
Sodium Borate 0.41 4.1 Decahydrate Potassium Chloride O . 14 1 . 4
Purite O . 01 0 . 1
Purified Water S to 100% q - S to 100 %
Compositions P, A, B and C, are prepared according to the following procedure.
1. Measure Purified Water to about 90% of the batch size and place in an appropriate beaker or container.
2. Begin mixing the water with a strong mixer (Rotosolver) to obtain a strong vortex.
3. Add the pre-weighed carboxymethylcellulose sodium into the strong vortex. Continue strong mixing for at least 1 hour.
4. Slow mixer to a slow speed.
5. Add and dissolve the pre-weighed polysorbate 80.
6. Add and dissolve the pre-weighed glycerin.
7. Add and dissolve the pre-weighed mannitol.
8. Add and dissolve the pre-weighed sodium citrate dehydrate.
9. Add and dissolve the pre-weighed boric acid. 10. Add and dissolve the pre-weighed sodium borate decahydrate.
11. Add and dissolve the pre-weighed potassium chloride.
12. Check pH and adjust if necessary. Target pH is 7.5 +/- 0.1.
13. Add and dissolve the pre-weighed Purite.
14. Add sufficient quantity of Purified Water to attain the final batch volume. This will provide the finished placebo formulation (P) .
Procedure for either 0.03% (A), 0.04% (B), 0.05% (C)
15. Measure the exact amount of Placebo (9815X) needed to satisfy the batch size requirements and place in a media bottle that contains a magnetic stir bar.
16. Add and dissolve the pre-weighed cyclosporine. Stir at a slow speed to avoid foaming. It will usually take overnight mixing to completely dissolve the cyclosporine.
17. After overnight mixing is completed, pump the cyclosporine solution through a Millipore Milligard pre- filter and a Pall Suporlife sterilizing filter and collect the filtrate aseptically. 18. The sterile filtrate can then be aseptically dispensed into multidose dropper bottles suitable for ophthalmic purpose.
19. The finished product should be tested for cyclosporine assay, pH, osmolality, viscosity, Purite, sterility, and antimicrobial effectiveness.
20. The finished product should be store at room temperature and protected from light.
Example 2
The following formulations were prepared. D and E were prepared by standard methods known in the art . F was prepared as described above for A-C except that Pemulen TR-2 was substituted for carboxymethylcellulose sodium, and the addition of the citrate and borate buffers were omitted.
Figure imgf000022_0001
Bioavailability
The compositions disclosed and used herein provide a therapeutically effective amount of cyclosporin A to a mammal. However, while not intending to limit the scope of the invention in any way, concentrations of cyclosporin A in the compositions may be significantly lower than those normally associated with a therapeutically effective concentration. For example, one commercial preparation, marketed as Restasis by Allergan, Inc., is a 0.05% cyclosporin A castor oil emulsion. Other compositions currently in development have concentrations of 0.1% or higher.
Reported herein are pharmacokinetic data for in vivo experiments on rabbits. However, the rabbit experiments are believed to be useful models for bioavailability in other mammals including humans. Thus, although bioavailability parameters are disclosed and featured in the claims, they should not be construed as limiting the treatment to rabbits only, but the compositions characterized and defined by bioavailability in rabbits are also contemplated for use in treatment in other mammals, particularly humans.
In one embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition AA. In another embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition BB.
In another embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition CC. In one embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition DD.
In another embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition EE.
In another embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition FF.
In one embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition GG.
In another embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition HH. In another embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition II.
In another embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition JJ.
In another embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition KK.
In another embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition LL.
In another embodiment, the composition provides more cyclosporin A to the cornea of a person than Composition MM. In one embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition AA.
In another embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition BB.
In another embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition CC.
In one embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition DD.
In another embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition EE. In another embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition FF.
In one embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition GG.
In another embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition HH.
In another embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition II.
In another embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition JJ. In another embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition KK.
In another embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition LL.
In another embodiment, the composition provides more cyclosporin A to the conjunctiva of a person than Composition MM.
In another embodiment, topical administration of one 35 μL drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 500 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration. In another embodiment, wherein topical administration of one 35 μL drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 1000 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration.
In another embodiment, topical administration of one 35 μL drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 1400 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration.
In another embodiment, wherein topical administration of one 35 μL drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 2000 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration.
In another embodiment, topical administration of one 35 μL drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 2400 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration.
In another embodiment, topical administration of one 35 μL drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 17000 ng of cyclosporin A per gram of cornea of said rabbit over a period of 24 hours after said topical administration.
In another embodiment, said composition is an aqueous solution containing from 0.005% to about 0.04% cyclosporin A, wherein topical administration of one 35 μL drop of said composition to each eye of a New Zealand rabbit provides at least about 17000 ng of cyclosporin A per gram of cornea to the corneas of said rabbit as determined by: topically administering said composition to each eye of each of 15 female New Zealand white rabbit test subjects; and determining the amount of cyclosporin A in the corneas of three subjects at times of about 0.5 hours, about 2 hours, about 6 hours, about 12 hours, and about 24 after administration to said subject; wherein the amount of cyclosporin A in the cornea is determined only once for each subject. In another embodiment said composition to each eye of a New Zealand rabbit provides at least about 30000 ng of cyclosporin A per gram of cornea to the corneas of said rabbit.
In another embodiment said composition to each eye of a New Zealand rabbit provides at least about 45000 ng of cyclosporin A per gram of cornea to the corneas of said rabbit.
In another embodiment said composition to each eye of a New Zealand rabbit provides at least about 95000 ng of cyclosporin A per gram of cornea to the corneas of said rabbit.
In another embodiment said composition to each eye of a New Zealand rabbit provides at least about 155000 ng of cyclosporin A per gram of cornea to the corneas of said rabbit.
In another embodiment, topical administration of one 35 μL drop of said composition to each eye of a female New Zealand white rabbit provides to the conjunctivas of said rabbit at least about 6000 ng of cyclosporin A per gram of conjunctiva of said rabbit over a period of 24 hours after said topical administration.
In another embodiment, said composition is an aqueous solution containing from 0.005% to about 0.04% cyclosporin A, wherein topical administration of one 35 μL drop of said composition to each eye of a New Zealand rabbit provides at least about 6000 ng of cyclosporin A per gram of conjunctiva to the conjunctivas of said rabbit as determined by: topically administering said composition to each eye of each of 15 female New Zealand white rabbit test subjects; and determining the amount of cyclosporin A in the conjunctivas of three subjects at times of about 0.5 hours, about 2 hours, about 6 hours, about 12 hours, and about 24 after administration to said subject; wherein the amount of cyclosporin A in the conjunctiva is determined only a single time for each subject.
In another embodiment said composition to each eye of a New Zealand rabbit provides at least about 5000 ng of cyclosporin A per gram of conjunctiva to the conjunctiva of said rabbit.
In another embodiment said composition to each eye of a New Zealand rabbit provides at least about 7000 ng of cyclosporin A per gram of conjunctiva to the conjunctiva of said rabbit.
In another embodiment said composition to each eye of a New Zealand rabbit provides at least about 10000 ng of cyclosporin A per gram of conjunctiva to the conjunctiva of said rabbit.
In another embodiment said composition to each eye of a New Zealand rabbit provides at least about 17000 ng of cyclosporin A per gram of conjunctiva to the conjunctiva of said rabbit. In another embodiment, the blood level of cyclosporin A is less than 0.1 mg/mL for a person for whom the composition has been administered twice a day topically to both eyes in 35 microliter drops for twelve months.
Pharmacokinetic Study 1 A 35 μL aliquot of one of three test formulations was topically administered to each eye of a female New Zealand White rabbit (n=3 rabbits/time point) . At 0.5 , 2, 6, 12, 24, 48 and 144 hours post-dose, cornea, conjunctiva, sclera, eyelid margin, nasolacrimal duct, and blood samples were collected. Samples collected from naϊve rabbits (n=2) served as pre-dose samples. The quantitation ranges were 0.2-40 ng/mL in blood, 0.1-200 ng in cornea and conjunctiva, 0.1-100 ng in eyelid margin and nasolacrimal duct, and 0.1-20 ng in sclera and lacrimal gland.
The pharmacokinetic parameters of cyclosporine A in ocular tissues following a single ophthalmic instillation of one of three 0.05% cyclosporine A formulations are summarized in Table 1 below: Table 1
Tissue/Matr
Composition F Composition E Compositon D ix
Cn13
AUC0-t AUC0-t AUC0-t x (ng*h tl/2 C N^max (ng*h tl/2 (ng*hr/ tl/2
(ng (hr) (ng/g) (hr) r/g) r/g) (ng/g) (hr) g)
/g)
40
Cornea 163000 41.3 1100 76200 41.7 536 29300 49.8 50
44
Conjunctiva 18100 11.3 2560 11600 5.57 694 5290 4.55 60
54
Sclera 6110 29.7 136 2840 24.8 53.0 1040 18.7 5
Eyelid 31
38300 42.5 2020 42200 38.1 2450 27700 24.4 Margin 20
Nasolacrimal 19
2190 NC 74.4 1190 NC 72.0 279 NC Duct 5
2.
Blood NC NC 0.441 NC NC BLQ BLQ NC 21
NC = Not calculable
BLQ = Below the limit of quantitation
Brief ly summari z ing , fol lowing a single ocular insti l lation of a 0 . 05 % cyclosporine A formulation , the highest cyclosporine A ocular tissue exposure levels were observed from Composition F, followed by the Composition E, followed by Composition D.
Materials Test Articles
Compositions D, E, and F, as described above, were used for these experiments.
Chemicals, Reagents and Supplies
All other chemicals were reagent grade or better. Animals
Species, Strain, Sex, Age, Size, Source, and
Identification
Female New Zealand White rabbits weighing 1.8 to 2.6 kg were purchased from Charles River (St. Constant, Quebec, Canada) . A permanent ear tag was used to identify animals.
Justification
Similarities between the ocular anatomies of rabbits and humans make the rabbit an attractive animal model .
Animal Husbandry- All animals were housed in environmentally- controlled facility with a time-controlled fluorescent lighting system providing a daily 12 -hour light/12 -hour dark period. Room temperature was maintained between 61 and 720F, and relative humidity between 30 and 70%. Airflow ranged from 10 to 30 air changes per hour. Temperature, humidity, and airflow were monitored by the Edstrom Watchdog system version 4.0. The animals were provided Certified Hi-Fiber Rabbit Diet. Diet certification and analysis were provided by the vendor. No analysis outside those provided by the manufacturer was performed.
Drinking water that was purified by a reverse osmosis process was offered ad libitum. Water was periodically analyzed for any contaminants that may interfere with the conduct of this study. The manufacturer conducted analysis of animal feed.
Animal Acclimation
During the acclimatization period at Allergan, animals were kept under daily observation for any change in general health or behavior. Rabbits were quarantined for at least five days prior to the start of the study. All animals appeared healthy prior to and for the duration of the study.
Animal Termination and Disposal
Animals were euthanized via injection of at least 1 mL of sodium pentobarbital into a marginal ear vein.
Study Design and Experimental Procedures Study Design
Table 1 Study design
Figure imgf000033_0001
Single bilateral dose, 3 rabbits (6 eyes and 3 blood samples) per time point. Two animals in group 4 were not dosed and were used as bioanalytical controls. Prior to dosing, 65 animals were weighed and assigned to 4 study groups. The study design is presented in Table 1. The four study groups are presented in the Table 2 below:
Table 2
Figure imgf000034_0001
n = Number of animals per group F = Female
Pretreatment Examinations
Prior to placement on study, a physical examination was performed on each animal. Gross observations were recorded prior to drug administration and immediately after ocular dose using a standardized data collection sheet .
Randomization
Prior to dosing, 65 animals were weighed and randomly assigned to four study groups.
Dosing Procedure:
Animals were dosed once by ocular instillation bilaterally at Hour 0 of the study. Immediately prior to dosing, the eye was inspected for any abnormalities, such as infection, red eye, or visible damage. Only animals without visible abnormalities were used. The lower eyelid was gently pulled out and away from the eye. Using a Gilson precision pipette, 35 μL of dosing solution was instilled into the lower cul-de-sac of each eye. The time of dose administration was recorded. The eye was gently held closed for approximately 5 seconds to ensure even dose distribution around the eye. Gross ocular observations were performed following dosing. The animal, including the dosed eyes, were subjectively evaluated for signs of irritation. Observations were recorded.
Mortality/Morbidity
Animals were observed for mortality/morbidity during the study.
Body Weights
Animals were weighed the day before dose administration and subsequently randomized.
Pre-necropsy Blood Collection
Blood was collected from each rabbit prior to euthanasia/necropsy. Animals were anesthetized with an intravenous injection of a ketamine/xylazine cocktail (87 mg/mL ketamine, 13 mg/mL xylazine) at a volume of 0.1 mL/kg. Blood was collected via cardiac puncture. Approximately 5 mL of blood was collected into 10 mL lavender top (K3 EDTA) tubes. Blood samples were stored at or below approximately -150C until bioanalysis.
Euthanasia
Animals were euthanized with an intravenous injection of commercial euthanasia solution following blood collection. Necropsy and Collection of Ocular Tissues
Ocular samples were collected from both eyes, blotted dry where applicable, weighed and placed in separate, appropriately labeled, silanized vials, at the time of necropsy. Both eyes were rinsed with LENS PLUS in order to clear residual surface formulation remaining on the ocular surface. Conjunctiva
The upper and lower conjunctiva from each eye were removed and pooled, weight recorded, placed into separate screw-cap glass 13x100 silanized test tubes and immediately placed on ice. Samples were stored at or below -15°C until bioanalysis.
Cornea The entire cornea was removed from each eye,- weight recorded, placed into separate screw-cap glass 13x100 silanized test tubes and immediately placed on ice. Samples were stored at or below -150C until bioanalysis.
Sclera
The sclera was removed from each eye,- weight recorded, placed into separate screw-cap glass 13x100 silanized test tubes and immediately placed on ice. Samples were stored at or below -150C until bioanalysis.
Nasolacrimal Duct
Tissue containing the nasolacrimal duct associated with each eye was removed; weight recorded, placed into screw-cap glass 13x100 silanized test tubes and immediately placed on ice. Samples were stored at or below -15°C until bioanalysis.
Eyelid Margin
The eyelid margins were removed from each eye,- weight recorded, placed into separate screw-cap glass 13x100 silanized test tubes and immediately placed on ice. Samples were stored at or below -150C until bioanalysis .
Sample Storage
Blood and ocular tissue samples were stored at or below -15°C until bioanalysis.
Bioanalysis Ocular tissue and blood concentrations were quantified using the following method.
Ocular tissue samples were extracted by soaking over night with 2.0 mL methanol at 40C. This was followed by a second soak with 2.0 mL methanol and shaking for approximately one hour at room temperature. An aliquot of 1 mL from a total of 4 mL organic extract was removed (all 4 mL were analyzed for lacrimal gland samples) , and internal standard added (20 μL of 500 ng/mL of CsG) . The methanolic extract was evaporated to dryness and reconstituted with 200 μL of 2 mM ammonium acetate/0.4% formic acid in 50:50 acetonitrile : water for LC MS/MS analysis. The bioanalytical procedure for analysis of blood samples involved addition of internal standard, CsG (10 μL of 500 ng/mL) to 0.5 mL aliquots of K3 EDTA- treated rabbit blood. Following incubation of blood sample for 30 minutes at 370C, the samples were acidified with 0.1 N HCL (2 mL) . Methyl t-butyl ether (4 mL) was added to each sample and mixed for 15 minutes. The organic layer was removed and made basic by addition of 0.1 N NaOH (2 mL) . The organic extract was separated from the aqueous layer, evaporated to dryness and reconstituted with 200 μL of 2 mM ammonium acetate/0.4% formic acid in 50:50 acetonitrile : water for LC MS/MS analysis. Aliquots (50 μL) of the reconstituted samples were analyzed by LC- MS/MS using a PE Sciex API 3000 mass spectrometer
(Applied Biosystems, Foster City, CA) , Leap autosampler (Carrboro, NC) , and HPLC pumps (Shimadzu Scientific Instruments, Columbia, MD) . Reverse-phase HPLC was performed on a Keystone BDS C8 column (3 μm, 2.1 x 50 mm, 65 0C) with solvent gradient elution (A=2mM ammonium acetate/0.4% formic acid in water and B=2mM ammonium acetate/0.4% formic acid in acetonitrile) at a flow rate of 0.3 mL/min. The precursor-product ion pairs used in MRM analysis were: 1203 (MH) +→ 425.5 for CsA and m/z 1217 (MH) +→ 425.5 for IS (Cyclosporin G) . The total analysis time was 5 min, with retention times of CsA and CsG at approximately 1.82 and 1.86 minutes, respectively. Data Treatment
Data Collection
• Pre and post treatment gross ocular examinations
• Body Weights: Randomization at Day -1
• Dosing Notes
• Mortality/Morbidity Blood Samples: Pre-necropsy
• Ocular Tissue Samples: Post-necropsy
Data Calculation and Outlier Analysis
All data was used in calculations unless omitted for reasons justified in the raw data.
Pharmacokinetic Analysis
Thermo Electron Watson™ (Philadelphia, PA) and Microsoft" Excel (Redmond, Washington) were used for pharmacokinetic calculations. The pharmacokinetic parameters listed below were calculated using a known non-compartmental approach (see Tang-Lui, et . al . Pharmaceutical Research, VoI 5, No. 4, 1988, 238-241) . The pharmacokinetic data was described using descriptive statistics such as mean and standard deviation whenever possible. Area under the concentration-time profile (AUC) values were reported as a composite AUC and whenever possible, ± standard error of the mean (SEM) .
PK Parameter Description
Qnax (ng/mL) or Maximum observed concentration (ng/g)
Tmax (hr) Time corresponding to maximum observed concentration
AUC o t (ng-hr/g) Area under concentration time curve from time zero to the last quantifiable time point using the random method for non- sequential sampling t i/2 (hr) Half-life
MRT (hr) Mean residence time
Values below the Limit of Quantitation and Number Rounding If more than half of the concentration values contributing to a calculation of the mean were below limit of quantitation (BLQ) , then the statistics were reported as non-calculable (NC) . If half or more of the values were quantifiable, then any BLQ values were replaced with a value of "0", and the mean and its standard deviation (SD) were calculated with these replaced values. The mean and standard deviation of the mean were calculated at each sampling time point within each treatment group. Whenever the sample size was less than or equal to 2, only mean values were listed. All mean values were reported to 3 significant figures and standard deviations were reported to the same decimal place as their respective mean values.
Protocol Deviations o Prior to collection of ocular tissue samples at the 6 hour time point, the eyes were not rinsed with Lens Plus® to clear any residual surface formulation remaining on the ocular surface. It is believed that this deviation will have minimal impact on the results derived from this study since in general this drug is rapidly absorbed from the ocular surface. In addition, blinking by the rabbits over 6 hours should also act to clear any residual surface formulation. o Abbreviations
Figure imgf000041_0001
Note : Not all abbreviations listed may appear in this report . Results and Discussion
Cornea
The mean concentrations and pharmacokinetic parameters are summarized in Tables 3 and 4. The concentration-time profiles of cyclosporine A in cornea following a single bilateral ocular administration of one of three 0.05% cyclosporine A formulations to rabbits are presented in Figure 1.
Table 3 Mean cornea concentrations of cyclosporine A following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits.
Figure imgf000042_0001
Mean values represent an average of n=6 a Concentration time points used to calculate t iA
Table 4 Pharmacokinetic parameters in cornea of cyclosporine A following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits
Figure imgf000043_0001
a An AUC interval of 0-144 hours was used for calculations for the three formulations
Composition F
Following a single bilateral ocular instillation of Composition F, cyclosporine A was rapidly absorbed into the cornea with a peak corneal concentration (Cmax) of 4050 ± 1220 ng/g, occurring 0.500 hours post-dose. The area under the concentration-time curve (AUC0-t) value through the last quantifiable time point was 163000 ± 7000 ng-hr/g and the AUC0-24 value was 59000 ng-hr/g. The terminal half -life (ti/2) was 41.3 hours and the mean residence time (MRT) was 50.3 hours.
Composition E Following a single bilateral ocular instillation of Composition E, cyclosporine A was absorbed into the cornea with Cmax value of 1100 ± 190 ng/g, occurring 2.00 hours post-dose. The AUC0-t value was 76200 ± 3300 ng-hr/g and the AUCo-24 value was 22100 ng-hr/g. The terminal ti/2 was 41.7 hours and the MRT was 56.5 hours. Composition D
Following a single bilateral ocular instillation of Composition D, cyclosporine A was absorbed into the cornea with a Cmax value of 536 ± 138 ng/g, occurring 6.00 hours post-dose. The AUC0-t value was 29300 ± 2000 ng-hr/g and the AUCo-24 value was 9450 ng-hr/g. The terminal ti/2 was 49.8 hours and the MRT was 61.6 hours.
Conjunctiva The mean concentrations and pharmacokinetic parameters are summarized in Tables 5 and 6. The concentration-time profiles of cyclosporine A in conjunctiva following a single bilateral ocular administration of one of three 0.05% cyclosporine A formulations to rabbits are presented in Figure 2.
Table 5 Mean conj unctiva concentrations of cyclosporine A following a single bilateral topical ocular instillation of one of three 0 . 05% cyclosporine A formulations to New Zealand White rabbits
Figure imgf000045_0001
Mean values represent an average of n=6 BLQ=Below the limit of quantitation a Concentration time points used to calculate t i/2
Table 6 Pharmacokinetic parameters in conjunctiva of cyclosporine A following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits,
Figure imgf000045_0002
An AUC interval of 0-48 hours was used for calculations An AUC interval of 0-24 hours was used for calculations
Composition F Following a single bilateral ocular instillation of Composition F, cyclosporine A was rapidly absorbed into the conjunctiva with a Cmax value of 4460 ± 650 ng/g, occurring 0.500 hours post-dose. The AUC0-t value was 18100 ± 800 ng-hr/g and the AUC0-24 value was 17100 ng-hr/g. The terminal ti/2 was 11.3 hours and the MRT was 7.37 hours.
Composition E
Following a single bilateral ocular instillation of Composition E, cyclosporine A was rapidly absorbed into the conjunctiva with a Cmax value of 2560 ± 1070 ng/g, occurring 0.500 hours post-dose. The AUC0-t value was
11600 ± 700 ng-hr/g. The terminal ti/2 was 5.57 hours and the MRT was 5.93 hours.
Composition D
Following a single bilateral ocular instillation of
Composition D, cyclosporine A was rapidly absorbed into the conjunctiva with a Cmax value of 694 + 410 ng/g, occurring 0.500 hours post-dose. The AUC0-t value was
5290 ± 480 ng-hr/g. The terminal ti/2 was 4.55 hours and the MRT was 6.07 hours.
Sclera The mean concentrations and pharmacokinetic parameters are summarized in Tables 7 and 8. The concentration-time profiles of cyclosporine A in sclera following a single bilateral ocular administration of one of three 0.05% cyclosporine A formulations to rabbits are presented in Figure 3. Table 7 Mean sclera concentrations of cyclosporine A following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits.
Figure imgf000047_0001
Mean values represent an average of n=6
BLQ=Below the limit of quantitation a Concentration time points used to calculate t i/2
Table 8 Pharmacokinetic parameters in sclera of cyclosporine A following a single bilateral topical ocular instillation of one of three 0 . 05% cyclosporine A formulations to New Zealand White rabbits
Figure imgf000048_0001
a An AUC interval of 0 - 144 hours was used for calculations b An AUC interval of 0 - 48 hours was used for calculations
Composition F
Following a single bilateral ocular instillation of Composition F, cyclosporine A was rapidly absorbed into the sclera with a Cmax value of 545 ± 98 ng/g, occurring 0.500 hours post-dose. The AUC0-t value was 6110 ± 260 ng-hr/g and the AUCo-24 value was 3900 ng-hr/g. The terminal ti/2 was 29.7 hours and the MRT was 25.3 hours.
Composition E Following a single bilateral ocular instillation of Composition E, cyclosporine A was rapidly absorbed into the sclera with a Cmax value of 136 ± 43 ng/g, occurring 0.500 hours post-dose. The AUC0-t value was 2840 ± 150 ng-hr/g and the AUC0-24 value was 1560 ng-hr/g. The terminal ti/2 was 24.8 hours and the MRT was 26.7 hours. Composition D
Following a single bilateral ocular instillation of Composition D, cyclosporine A was absorbed into the sclera with a Cmax value of 53.0 ± 10.9 ng/g, occurring 6.00 hours post-dose. The AUC0-t value was 1040 ± 50 ng-hr/g and the AUCo-24 value was 792 ng-hr/g. The terminal ti/2 was 18.7 hours and the MRT was 23.8 hours.
Eyelid Margin The mean concentrations and pharmacokinetic parameters are summarized in Tables 9 and 10. The concentration-time profiles of cyclosporine A in the eyelid margin following a single bilateral ocular administration of one of three 0.05% cyclosporine A formulations to rabbits are presented in Figure 4.
Table 9 Mean eyelid margin concentrations of cyclosporine A following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits.
Figure imgf000050_0001
Mean values represent an average of n=6 a Concentration time points used to calculate t 1/2
Table 10 Pharmacokinetic parameters in eyelid margin of cyclosporine A following a single bilateral topical ocular instillation of one of three 0 . 05% cyclosporine A formulations to New Zealand White rabbits .
Figure imgf000050_0002
An AUC interval of 0 - 144 hours was used for calculations for the three formulations
Composition F Following a single bilateral ocular instillation of Composition F, cyclosporine A was rapidly absorbed into the eyelid margin with a Cmax value of 3120 ± 1040 ng/g, occurring 0.500 hours post-dose. The AUC0-t value was 38300 ± 5300 ng-hr/g and the AUC0-24 value was 19900 ng-hr/g. The terminal ti/2 was 42.5 hours and the MRT was 40.5 hours.
Composition E
Following a single bilateral ocular instillation of Composition E, cyclosporine A was rapidly absorbed into the eyelid margin with a Cmax value of 2020 ± 980 ng/g, occurring 0.500 hours post-dose. The AUC0-t value was 42200 ± 10800 ng-hr/g and the AUC0-24 value was 17600 ng-hr/g. The terminal ti/2 was 38.1 hours and the MRT was 38.4 hours.
Composition D
Following a single bilateral ocular instillation of Composition D, cyclosporine A was absorbed into the eyelid margin with a Cmax value of 2450 ± 970 ng/g, occurring 2.00 hours post-dose. The AUC0-t value was 27700 ± 3300 ng-hr/g and the AUC0-24 value was 18000 ng-hr/g. The terminal ti/2 was 24.4 hours and the MRT was 21.9 hours.
Nasolacrimal Duct
The mean concentrations and pharmacokinetic parameters are summarized in Tables 11 and 12. The concentration-time profiles of cyclosporine A in nasolacrimal duct tissue following a single bilateral ocular administration of one of three 0.05% cyclosporine A formulations to rabbits are presented in Figure 5.
Table 11 Mean nasolacrimal duct concentrations of cyclosporine A following a single bilateral topical ocular instillation of one of three 0 . 05% cyclosporine A formulations to New Zealand White rabbits
Figure imgf000053_0001
Mean values represent an average of n= BLQ=Below the limit of quantitation
Table 12 Pharmacokinetic parameters in nasolacrimal duct of Cyclosporine A following a single bilateral topical ocular instillation of one of three 0 . 05% cyclosporine A formulations to New Zealand White rabbits .
Figure imgf000053_0002
NC=Not calculable a An AUC interval of 0 - 144 hours was used for calculations b An AUC interval of 0 - 48 hours was used for calculations c An AUC interval of 0 - 12 hours was used for calculations d A time interval of 0 - 12 hours was used for calculations Composition F
Following a single bilateral ocular instillation of Composition F, cyclosporine A rapidly drained into and was then absorbed into the nasolacrimal duct tissue with a Cmax value of 195 ± 201 ng/g, occurring 0.500 hours post-dose. The AUC0-t value was 2190 ± 350 ng-hr/g and the AUCo-12 value was 478 ± 86 ng-hr/g. The MRT was 17.6 hours .
Composition E Following a single bilateral ocular instillation of Composition E, cyclosporine A rapidly drained into and was then absorbed into the nasolacrimal duct tissue with a Cmax value of 74.4 + 20.9 ng/g, occurring 0.500 hours post-dose. The AUC0-t value was 1190 ± 210 ng-hr/g and the AUCo-12 value was 465 ± 106 ng-hr/g. The MRT was 24.7 hours .
Composition D
Following a single bilateral ocular instillation of Composition D, cyclosporine A rapidly drained into and was then absorbed into the nasolacrimal duct tissue with a Cmax value of 72.0 ± 91.7 ng/g, occurring 0.500 hours post -dose. The AUC0-t value was 279 ± 39 ng-hr/g. The
MRT was 12.1 hours.
Blood
The mean concentrations of cyclosporine A in blood are summarized in Table 13. Table 13 Mean blood concentrations of Cyclosporine A following a single bilateral topical ocular instillation of one of three 0.05% cyclosporine A formulations to New Zealand White rabbits.
Figure imgf000055_0001
Mean values represent an average of n=3 BLQ=Below the limit of quantitation
Composition F
Following a single bilateral ocular instillation of Composition F , cyclosporine A was detected at 0 . 5 and 2 hours post -dose in the blood at concentrations of 2 . 21 + 0 . 33 ng/mL and 0 . 463 ± 0 . 021 ng/mL , respectively . Cyclosporine A levels were below the limit of quantitation at all subsequent time points .
Composition E
Following a single bilateral ocular instillation of Composition E, cyclosporine A was detected at 0.5 hours post-dose in the blood at a concentration of 0.441 + 0.126 ng/mL. Cyclosporine A levels were below the limit of quantitation at all subsequent time points. Composition D
Following a single bilateral ocular instillation of Composition D, cyclosporine A levels were below the limit of quantitation at all time points.
Administration of Composition F to rabbits generally delivered the highest levels of cyclosporine A to ocular tissues, on average a 5-fold increase in area under the concentration-time profile (AUC) was observed when compared to Composition D. Administration of Composition E to rabbits resulted on average in a 2-fold increase in AUC when compared to Composition D. The pharmacokinetic profile observed following Composition D administration to New Zealand White rabbits in this study was in good agreement with previously reported data.
In general, the terminal half -life and mean residence time observed were greatest for Composition F, followed by the Composition E, followed by Composition D. Thus, AUC values were reported to the last quantifiable time point, in addition to AUC through 24 hours for cornea, conjunctiva, sclera and eyelid margin and AUC through 12 hours for nasolacrimal duct to make an assessment over the same interval as to the drug levels achieved following once a day dosing. Overall, the trends observed when comparing AUC0-t values were consistent with the trends observed when comparing AUCo-24
Figure imgf000056_0001
In conclusion, following a single ocular instillation of a 0.05% cyclosporine A formulation, the highest cyclosporine A ocular tissue exposure levels were observed when drug was formulated as an aqueous Composition F, followed by the Composition E followed by Composition D. A concomitant trend was observed in blood drug exposure . While not intending to limit the scope of the invention, it is believed that these pharmacokinetic results suggest that significantly lower concentrations of cyclosporin A may be used in topical ophthalmic compositions than previously known and still achieve a therapeutically effective amount cyclosporin A.
Pharmacokinetic Study 2
The compositions below were prepared in an analogous manner to compositions D, E, and F.
Purified Water 1 QS 1 QS 1 N/A
A pharmacokinetic study was carried out using similar analytical methods to those already described. The parameters are shown below. * Test Formulations: G, H, and D
• Animal species/strain: Rabbit NZW
• Gender : Female • Number: 2 rabbits/timepoint (2 rabbits blanks)
• Dosing Route: Topical ocular • Dosing Regimen: Bilateral, QD (Aqueous) /BID (Composition D) -5days
• Dose Volume: 35 μL • Time points Day 1 and Day 5-0.5, 2 , 6 , 12, 24 hr post dose
• Assay Method: LC-MS/MS • Analyte: Cyclosporine A
Data Analysis: Cmax< AUC0 -24- AUC dose normalized
The results in cornea, tear, and blood are shown in the tables below. Table 14. Cyclosporin bioavailability in the cornea.
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000059_0002
n=2 rabbits/timepoint
BLQ-Below the limit of detection (0.2 ng/mL)
Table 16. Cyclosporin bioavailability in the tears.
Figure imgf000059_0003
Standard Compositions
These compositions (AA-MM) are particularly contemplated for use as standards for comparison for characterization of the compositions disclosed herein.
The following compositions are intended to mean those identical to those disclosed in Kanai et . al . , Transplantation Proceedings, VoI 21, No 1 (February), 1989: 3150-3152, which is incorporated by reference herein:
Composition AA: a solution consisting of 0.025% cyclosporin A, 40 mg/mL alpha cyclodextrin, and water; Composition BB: a solution consisting of 0.009% cyclosporin A, 20 mg/mL alpha cyclodextrin, and water; and
Composition CC: a solution consisting of 0.003% cyclosporin A, 10 mg/mL alpha cyclodextrin, and water. The following composition is intended to mean those identical to that disclosed in Cheeks et . al . , Current Eye Research, VoI 11, No 7 (1992), 641-649, which is incorporated by reference herein:
Composition DD: an alpha cyclodextrin solution at 40 mg/mL containing 0.025% cyclosporin A.
The following composition is intended to mean that identical that disclosed in Tamilvanan, Stp Pharma Sci Nov-Dec,- 11(6) :421-426, which is incorporated by reference herein, except that the concentration of cyclosporin A is different.
Composition EE: an emulsion consisting of cyclosporin A (0.05 w/w%) , castor oil (2.5 w/w%) , stearylamine (0.12 w/w%) , α-tocopherol (0.01 w/w%) , benzalkonium chloride (0.01 w/w%) and water up to 100 w/w% . The following compositions are intended to mean those identical to Samples C-E disclosed in United States Patent No. 5,051,402 (column 7) . The entire disclosure is incorporated herein by reference.
Composition FF: 0.25 mL/mL of cyclosporin A, 40 mg/mL of α-cyclodextrin, and 7.79 mg/mL of sodium chloride; Composition GG: 0.10 mL/mL of cyclosporin A, 20 mg/mL of α-cyclodextrin, and 8.40 mg/mL of sodium chloride; and
Composition HH: 0.05 mL/mL of cyclosporin A, 10 mg/mL of α-cyclodextrin, and 8.70 mg/mL of sodium chloride. The following composition is intended to mean that identical that disclosed in Abdulrizak, Stp Pharma Sci Nov-Dec,- 11(6) :427-432, which is incorporated by reference herein, except that the concentration of cyclosporin A is different. Composition II: an emulsion consisting of cyclosporin A (0.05 w/w%) , castor oil (2.5 w/w%) , Poloxamer 188, (0.425 w/w%) , glycerol (2.25 w/w%) , Lipoid E-80 (0.5 w/w%) , stearylamine (0.12 w/w%) , tocopherol (0.01 w/w%) , benzalkonium chloride (0.01 w/w%) , and water. The following composition is intended to mean that identical to that disclosed in Kuwano Mitsuaki et al . Pharm Res 2002 Aug,- 19 (1) : 108-111.
Composition JJ: a solution consisting of cyclosporine A (0.0865%), ethanol (0.1%), MYS-40 (2%), HPMC (0.3 w/v%) , sodium dihydrogen phosphate (0.2 w/v%) , and disodium EDTA (0.01% w/v%) , sodium chloride to adjust the tonicity to 287 mOsm, and water.
Composition KK is intended to mean that disclosed in US20010041671, incorporated by reference herein, as Formulation 1, on Table 1. Composition LL is that disclosed in US20010041671 as Formulation 3, except that the concentration of cyclosporine is reduced.
Composition KK: cyclosporine A (0.02%), sodium hyaluronate (0.05%), Tween 80 (0.05%), Na2HPO4 • 12H2O (0.08%), sorbitol (5.46%), purified water added to 100 mL, pH 7.0-7.4, and mosm/L = 295-305. Composition LL: cyclosporine A (0.2%), sodium hyaluronate (0.10%), Tween 80 (5.00%), Na2HPO4 • 12H2O (0.08%), sorbitol (5.16%), purified water added to 100 mL, pH 7.0-7.4, and mosm/L = 295-305.
The following composition is intended to mean that disclosed in Example 2 of US 5,951,971, incorporated herein by reference.
Composition MM: cyclosporine A (0.025 g) , polyoxyl 40 stearate (0.5g), hydroxypropyl methylcellulose (0.2g), butylated hydroxytoluene (0.0005 g) , ethanol (0.1 g) , sodium chloride (0.73 g) , sodium dihydrogen phosphate (0.2 g) , sodium edethate (0.1 g) , sodium hydroxide to adjust pH to 6.0, and water to make 100 mL . In another embodiment the composition provides more cyclosporin A than Composition AA provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition AA, wherein the drop of said composition and the drop of Composition AA are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition BB provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition BB, wherein the drop of said composition and the drop of Composition BB are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition CC provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition CC, wherein the drop of said composition and the drop of Composition CC are the same volume . In another embodiment the composition provides more cyclosporin A than Composition DD provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition DD, wherein the drop of said composition and the drop of Composition DD are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition EE provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition EE, wherein the drop of said composition and the drop of Composition EE are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition FF provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition FF, wherein the drop of said composition and the drop of composition FF are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition GG provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition GG, wherein the drop of said composition and the drop of composition GG are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition HH provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition HH, wherein the drop of said composition and the drop of composition HH are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition II provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition II, wherein the drop of said composition and the drop of composition II are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition JJ provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition JJ, wherein the drop of said composition and the drop of composition JJ are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition KK provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition KK, wherein the drop of said composition and the drop of composition KK are the same volume . In another embodiment the composition provides more cyclosporin A than Composition LL provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition LL, wherein the drop of said composition and the drop of composition LL are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition MM provides to the cornea of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition MM, wherein the drop of said composition and the drop of composition MM are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition AA provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition AA, wherein the drop of said composition and the drop of Composition AA are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition BB provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition BB, wherein the drop of said composition and the drop of Composition BB are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition CC provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition CC, wherein the drop of said composition and the drop of Composition CC are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition DD provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition DD, wherein the drop of said composition and the drop of Composition DD are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition EE provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition EE, wherein the drop of said composition and the drop of Composition EE are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition FF provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition FF, wherein the drop of said composition and the drop of composition FF are the same volume . In another embodiment the composition provides more cyclosporin A than Composition GG provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition GG, wherein the drop of said composition and the drop of composition GG are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition HH provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition HH, wherein the drop of said composition and the drop of composition HH are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition II provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition II, wherein the drop of said composition and the drop of composition II are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition JJ provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition JJ, wherein the drop of said composition and the drop of composition JJ are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition KK provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition KK, wherein the drop of said composition and the drop of composition KK are the same volume . In another embodiment the composition provides more cyclosporin A than Composition LL provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition LL, wherein the drop of said composition and the drop of composition LL are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition MM provides to the conjunctiva of a female New Zealand white rabbit 30 minutes after topical ocular administration of one drop of said composition or Composition MM, wherein the drop of said composition and the drop of composition MM are the same volume .
Comparison of two compositions in a person or animal can be carried out by, among other means, administering the claimed composition to one eye and the second composition to the second eye.
In another embodiment the composition provides more cyclosporin A than Composition AA provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition AA, wherein the drop of said composition and the drop of Composition AA are the same volume . In another embodiment the composition provides more cyclosporin A than Composition BB provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition BB, wherein the drop of said composition and the drop of Composition BB are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition CC provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition CC, wherein the drop of said composition and the drop of Composition CC are the same volume . In another embodiment the composition provides more cyclosporin A than Composition DD provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition DD, wherein the drop of said composition and the drop of Composition DD are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition EE provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition EE, wherein the drop of said composition and the drop of Composition EE are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition FF provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition FF, wherein the drop of said composition and the drop of composition FF are the same volume . In another embodiment the composition provides more cyclosporin A than Composition GG provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition GG, wherein the drop of said composition and the drop of composition GG are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition HH provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition HH, wherein the drop of said composition and the drop of composition HH are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition II provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition II, wherein the drop of said composition and the drop of composition II are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition JJ provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition JJ, wherein the drop of said composition and the drop of composition JJ are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition KK provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition KK, wherein the drop of said composition and the drop of composition KK are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition LL provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition LL, wherein the drop of said composition and the drop of composition LL are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition MM provides to the cornea of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition MM, wherein the drop of said composition and the drop of composition MM are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition AA provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition AA, wherein the drop of said composition and the drop of Composition AA are the same volume . In another embodiment the composition provides more cyclosporin A than Composition BB provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition BB, wherein the drop of said composition and the drop of Composition BB are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition CC provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition CC, wherein the drop of said composition and the drop of Composition CC are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition DD provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition DD, wherein the drop of said composition and the drop of Composition DD are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition EE provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition EE, wherein the drop of said composition and the drop of Composition EE are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition FF provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition FF, wherein the drop of said composition and the drop of composition FF are the same volume. In another embodiment the composition provides more cyclosporin A than Composition GG provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition GG, wherein the drop of said composition and the drop of composition GG are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition HH provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition HH, wherein the drop of said composition and the drop of composition HH are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition II provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition II, wherein the drop of said composition and the drop of composition II are the same volume.
In another embodiment the composition provides more cyclosporin A than Composition JJ provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition JJ, wherein the drop of said composition and the drop of composition JJ are the same volume.
In another embodiment the composition provides more cyclosporin A than Composition KK provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition KK, wherein the drop of said composition and the drop of composition KK are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition LL provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition LL, wherein the drop of said composition and the drop of composition LL are the same volume .
In another embodiment the composition provides more cyclosporin A than Composition MM provides to the conjunctiva of a female New Zealand white rabbit over a period of 24 hours after topical ocular administration of one drop of said composition or Composition MM, wherein the drop of said composition and the drop of composition MM are the same volume .
In one embodiment, wherein topical administration of one 35 μL drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 500 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration.
In another embodiment, topical administration of one 35 μL drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 2000 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration. In another embodiment, topical administration of one 35 μL drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 2400 ng of cyclosporin A per gram of cornea of said rabbit at 30 minutes after said topical administration.
In another embodiment, topical administration of one 35 μL drop of said composition to each eye of a female New Zealand white rabbit provides to the corneas of said rabbit at least about 17000 ng of cyclosporin A per gram of cornea of said rabbit over a period of 24 hours after said topical administration.
In another embodiment, topical administration of one 35 μL drop of said composition to each eye of a female New Zealand white rabbit provides to the conjunctivas of said rabbit at least about 3300 ng of cyclosporin A per gram of conjunctiva of said rabbit over a period of 24 hours after said topical administration.
In another embodiment, said composition is an aqueous solution containing from 0.005% to about 0.04% cyclosporin A, wherein topical administration of one 35 μL drop of said composition to each eye of a New Zealand rabbit provides at least about 17000 ng of cyclosporin A per gram of cornea to the corneas of said rabbit as determined by: topically administering said composition to each eye of each of 15 female New Zealand white rabbit test subjects, and determining the amount of cyclosporin A in the corneas of three subjects at times of about 0.5 hours, about 2 hours, about 6 hours, about 12 hours, and about 24 after administration to said subject, wherein the amount of cyclosporin A in the cornea is determined only once for each subject.
In another embodiment, said composition is an aqueous solution containing from 0.005% to about 0.04% cyclosporin A, wherein topical administration of one 35 μL drop of said composition to each eye of a New Zealand rabbit provides at least about 17000 ng of cyclosporin A per gram of conjunctiva to the conjunctivas of said rabbit as determined by: topically administering said composition to each eye of each of 15 female New Zealand white rabbit test subjects, and determining the amount of cyclosporin A in the conjunctivas of three subjects at times of about 0.5 hours, about 2 hours, about 6 hours, about 12 hours, and about 24 after administration to said subject, wherein the amount of cyclosporin A in the conjunctiva is determined only a single time for each subject. As mentioned above, these compositions are suitable for use in other mammals other than rabbits, including humans. Thus, any composition in the claims or elsewhere which is characterized by in vivo rabbit bioavailability testing is contemplated for use in a person or in another mammal . Defining a composition in terms of bioavailability in rabbits should not be construed to limit a method of treatment using the composition to use on rabbits, but treatment with the composition should be construed to include treatment on humans and other mammals. The foregoing description details specific methods and compositions that can be employed to practice the present invention, and represents the best mode contemplated. However, it is apparent for one of ordinary skill in the art that further compositions with the desired pharmacological properties can be prepared in an analogous manner. Thus, however detailed the foregoing may appear in text, it should not be construed as limiting the overall scope hereof; rather, the ambit of the present invention is to be governed only by the lawful construction of the claims.

Claims

What is claimed is:
1. A method of treating loss of corneal sensitivity comprising administering a composition comprising cyclosporin A at a concentration of from about 0.0001% (w/v) to less than about 0.05% (w/v) to a person in need thereof .
2. The method of claim 1 wherein the composition comprises cyclosporin A at a concentration of from 0.01% (w/v) to 0.02% (w/v) and a preservative.
3. The method of claim 2 wherein the concentration of cyclosporin A in the composition is about 0.015% (w/v) .
4. The method of claim 1 wherein the concentration of cyclosporin A in the composition about 0.04% (w/v) .
5. The method of claim 1 wherein the concentration of cyclosporin A in the composition is about 0.005% (w/v) .
6. The method of claim 1 wherein the loss of corneal sensitivity is related to surgery affecting the cornea or viral infection.
7. The method of claim 6 wherein the loss of corneal sensitivity is associated with keratorefractive surgery or penetrating keratoplasty.
8. The method of claim 7 wherein the loss of corneal sensitivity is caused by the person having radial keratotomy.
9. The method of claim 7 wherein the loss of corneal sensitivity is caused by photorefractive keratotomy.
10. The method of claim 7 wherein the loss of corneal sensitivity is caused by laser-assisted in situ keratomileusis .
11. The method of claim 7 wherein the loss of corneal sensitivity is caused by laser assisted sub-epithelial keratomileusis .
12. The method of claim 7 wherein the loss of corneal sensitivity is caused by SB-LASIK.
13. The method of claim 7 wherein the loss of corneal sensitivity is caused by EPI-LASIK.
14. The method of claim 6 wherein the loss of corneal sensitivity is caused by viral infection.
15. The method of claim 14 wherein the viral infection is HSV-I.
16. The method of claim 14 wherein the viral infection is HSV-2.
17. The method of claim 14 wherein the viral infection is VZV.
18. The method of claim 2 wherein the concentration of cyclosporin A in the composition is about 0.0015% (w/v) .
19. A liquid composition comprising cyclosporin A at a concentration of about 0.0015% (w/v) .
PCT/US2008/076756 2007-09-20 2008-09-18 Cyclosporin compositions WO2009099467A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP08872212.9A EP2190407B1 (en) 2007-09-20 2008-09-18 Cyclosporin compositions
MX2010003045A MX2010003045A (en) 2007-09-20 2008-09-18 Cyclosporin compositions.
JP2010525937A JP2010540446A (en) 2007-09-20 2008-09-18 Cyclosporine composition
BRPI0816995 BRPI0816995A2 (en) 2007-09-20 2008-09-18 Cyclosporine Compositions
AU2008349774A AU2008349774A1 (en) 2007-09-20 2008-09-18 Cyclosporin compositions
CA2700182A CA2700182A1 (en) 2007-09-20 2008-09-18 Cyclosporin compositions
CN200880113223A CN101835463A (en) 2007-09-20 2008-09-18 Herbicide-safener combination
IL204614A IL204614A0 (en) 2007-09-20 2010-03-18 Cyclosporin compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/858,200 2007-09-20
US11/858,200 US20080146497A1 (en) 2006-07-25 2007-09-20 Cyclosporin Compositions

Publications (2)

Publication Number Publication Date
WO2009099467A2 true WO2009099467A2 (en) 2009-08-13
WO2009099467A3 WO2009099467A3 (en) 2009-10-22

Family

ID=39528114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/076756 WO2009099467A2 (en) 2007-09-20 2008-09-18 Cyclosporin compositions

Country Status (12)

Country Link
US (1) US20080146497A1 (en)
EP (1) EP2190407B1 (en)
JP (1) JP2010540446A (en)
KR (1) KR20100091946A (en)
CN (1) CN101835463A (en)
AU (1) AU2008349774A1 (en)
BR (1) BRPI0816995A2 (en)
CA (1) CA2700182A1 (en)
IL (1) IL204614A0 (en)
MX (1) MX2010003045A (en)
RU (1) RU2010112472A (en)
WO (1) WO2009099467A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013140071A1 (en) 2012-03-22 2013-09-26 Laboratoires Thea Cyclosporin a-based aqueous ophthalmic solution
US9266927B2 (en) 2012-06-01 2016-02-23 Allergan, Inc. Cyclosporin A analogs
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
AU2008310956B2 (en) 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US20100279951A1 (en) * 2009-05-01 2010-11-04 Aileen Morgan Method of treating allergic conjunctivitis with cyclosporin compositions
US9017725B2 (en) * 2009-06-09 2015-04-28 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
AU2012351948A1 (en) * 2011-12-16 2014-07-10 Allergan, Inc. Ophthalmic compositions comprising polyvinyl capralactam - polyvinyl acetate - polyethylene glycol graft copolymer
CA2955037A1 (en) * 2014-07-18 2016-01-21 Allergan, Inc. Suspension compositions of cyclosporin a for subconjunctival and periocular injection
KR101587412B1 (en) * 2014-10-17 2016-01-21 주식회사 휴온스 Ophthalmic Composition Comprising Cyclosporine and Trehalose
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
RU2762767C1 (en) * 2020-09-15 2021-12-22 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Министерства здравоохранения Российской Федерации Method for determining the corneal tactile sensitivity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051402A (en) * 1987-06-04 1991-09-24 Sankyo Company, Limited Pharmaceutical composition containing cyclosporin in admixture with α-
WO2007011880A2 (en) * 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3851152T2 (en) * 1987-09-03 1995-01-26 Univ Georgia CYCLOSPORINE EYE PRODUCTS.
ES2098739T3 (en) * 1992-05-13 1997-05-01 Sandoz Ltd OPHTHALMIC COMPOSITIONS CONTAINING A CYCLOSPORIN.
DK2153819T3 (en) * 2000-07-14 2012-12-03 Allergan Inc Use of a solubility enhancing component in an aqueous composition comprising brimonidine tartrate
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051402A (en) * 1987-06-04 1991-09-24 Sankyo Company, Limited Pharmaceutical composition containing cyclosporin in admixture with α-
WO2007011880A2 (en) * 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
REYNOLDS S A ET AL: "Therapeutic options for the management of early neurotrophic keratopathy: A case report and review" OPTOMETRY - JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION, ELSEVIER, NL, vol. 77, no. 10, 1 October 2006 (2006-10-01), pages 503-507, XP025253438 ISSN: 1529-1839 [retrieved on 2006-10-01] *
See also references of EP2190407A2 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013140071A1 (en) 2012-03-22 2013-09-26 Laboratoires Thea Cyclosporin a-based aqueous ophthalmic solution
FR2988297A1 (en) * 2012-03-22 2013-09-27 Thea Lab AQUEOUS OPHTHALMIC SOLUTION FROM CICLOSPORINE WITHOUT PRESERVATIVE
US8969305B2 (en) 2012-03-22 2015-03-03 Laboratories Thea Aqueous ophthalmic solution based on cyclosporin
RU2634267C2 (en) * 2012-03-22 2017-10-24 Лаборатуар Теа Aqueous ophthalmic solution based on cyclosporin a
US9266927B2 (en) 2012-06-01 2016-02-23 Allergan, Inc. Cyclosporin A analogs
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized

Also Published As

Publication number Publication date
CN101835463A (en) 2010-09-15
KR20100091946A (en) 2010-08-19
MX2010003045A (en) 2010-04-29
AU2008349774A1 (en) 2009-08-13
BRPI0816995A2 (en) 2015-03-24
IL204614A0 (en) 2010-11-30
CA2700182A1 (en) 2009-08-13
WO2009099467A3 (en) 2009-10-22
RU2010112472A (en) 2011-10-27
EP2190407A2 (en) 2010-06-02
US20080146497A1 (en) 2008-06-19
EP2190407B1 (en) 2016-12-07
JP2010540446A (en) 2010-12-24

Similar Documents

Publication Publication Date Title
US20220409693A1 (en) Cyclosporin compositions
EP2190407B1 (en) Cyclosporin compositions
US20230241030A1 (en) Macrogol 15 hydroxystearate formulations
US20150366799A1 (en) Method of treating allergic conjunctivitis with cyclosporin compositions
AU2016203191B2 (en) Cyclosporin compositions
AU2022202326A1 (en) Cyclosporin compositions
CN101896160A (en) Cyclosporin compositions

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880113223.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08872212

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2700182

Country of ref document: CA

Ref document number: 204614

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008349774

Country of ref document: AU

Ref document number: MX/A/2010/003045

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 584136

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010525937

Country of ref document: JP

REEP Request for entry into the european phase

Ref document number: 2008872212

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008872212

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2414/DELNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008349774

Country of ref document: AU

Date of ref document: 20080918

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107008509

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010112472

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0816995

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100319